Expression	O
of	O
NFAT-family	B-protein
proteins	I-protein
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

NFAT	B-protein
proteins	I-protein
constitute	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
mediating	O
signal	O
transduction	O
.	O

Using	O
a	O
panel	O
of	O
specific	O
antisera	O
in	O
immunoprecipitation	O
assays	O
,	O
we	O
found	O
that	O
NFATp	B-protein
(	O
135	B-protein
kDa	I-protein
)	O
is	O
constitutively	O
expressed	O
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
,	O
while	O
synthesis	O
of	O
NFATc	B-protein
(	O
predominant	O
form	O
of	O
86	B-protein
kDa	I-protein
)	O
is	O
induced	O
by	O
ionomycin	O
treatment	O
.	O

NFAT4/x	B-protein
was	O
very	O
weakly	O
expressed	O
in	O
unstimulated	O
cells	O
,	O
and	O
its	O
level	O
did	O
not	O
increase	O
upon	O
treatment	O
with	O
activating	O
agents	O
.	O

NFAT3	B-protein
protein	I-protein
was	O
not	O
observed	O
under	O
any	O
conditions	O
.	O

Higher-molecular-weight	B-protein
species	I-protein
of	O
NFATc	B-protein
(	O
of	O
110	O
and	O
140	O
kDa	O
)	O
were	O
also	O
detected	O
.	O

In	O
addition	O
,	O
translation	O
of	O
NFATc	B-RNA
mRNA	I-RNA
apparently	O
initiates	O
at	O
two	O
different	O
AUG	B-DNA
codons	I-DNA
,	O
giving	O
rise	O
to	O
proteins	O
that	O
differ	O
in	O
size	O
by	O
36	O
amino	O
acids	O
.	O

Additional	O
size	O
heterogeneity	O
of	O
both	O
NFATc	B-protein
and	O
NFATp	B-protein
results	O
from	O
phosphorylation	O
.	O

In	O
contrast	O
to	O
ionomycin	O
treatment	O
,	O
exposure	O
of	O
cells	O
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
plus	O
anti-CD28	B-protein
did	O
not	O
induce	O
NFATc	B-protein
,	O
indicating	O
that	O
under	O
these	O
conditions	O
,	O
interleukin-2	B-protein
synthesis	O
by	O
these	O
cells	O
is	O
apparently	O
independent	O
of	O
NFATc	B-protein
.	O

In	O
DNA	O
binding	O
assays	O
,	O
both	O
PMA	O
plus	O
anti-CD28	B-protein
and	O
PMA	O
plus	O
ionomycin	O
resulted	O
in	O
nuclear	B-protein
NFAT	I-protein
.	O

Surprisingly	O
,	O
the	O
PMA-ionomycin-induced	O
synthesis	O
of	O
NFATc	B-protein
that	O
was	O
detected	O
by	O
immunoprecipitation	O
was	O
not	O
mirrored	O
in	O
the	O
DNA	O
binding	O
assays	O
:	O
nearly	O
all	O
of	O
the	O
activity	O
was	O
due	O
to	O
NFATp	B-protein
.	O

This	O
is	O
the	O
first	O
study	O
of	O
expression	O
of	O
all	O
family	O
members	O
at	O
the	O
protein	O
level	O
in	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BroLoGYy	NULL
,	NULL
May	NULL
1997	NULL
,	NULL
p.	NULL
2475-2484	NULL
0270-7306/97/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1997	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

17	NULL
,	NULL
No	NULL
.	NULL

5	NULL
Expression	NULL
of	NULL
NFAT-Family	NULL
Proteins	NULL
in	NULL
Normal	NULL
Human	NULL
T	NULL
Cells	NULL
LYUDMILA	NULL
LYAKH	NULL
,	NULL
*	NULL
PARITOSH	NULL
GHOSH	NULL
,	NULL
*¢	NULL
anp	NULL
NANCY	NULL
R.	NULL
RICE'*	NULL
Molecular	NULL
Biology	NULL
of	NULL
Retroviruses	NULL
Section	NULL
,	NULL
Molecular	NULL
Basis	NULL
of	NULL
Carcinogenesis	NULL
Laboratory	NULL
,	NULL
ABL-Basic	NULL
Research	NULL
Program	NULL
,	NULL
``	NULL
and	NULL
Laboratory	NULL
of	NULL
Experimental	NULL
Immunology	NULL
,	NULL
Division	NULL
of	NULL
Basic	NULL
Science	NULL
,	NULL
SAIC	NULL
,	NULL
``	NULL
NCI-Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
Frederick	NULL
,	NULL
Maryland	NULL
21702-1201	NULL
Received	NULL
25	NULL
July	NULL
1996/Returned	NULL
for	NULL
modification	NULL
27	NULL
September	NULL
1996/Accepted	NULL
12	NULL
December	NULL
1996	NULL
NFAT	NULL
proteins	NULL
constitute	NULL
a	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
mediating	NULL
signal	NULL
transduction	NULL
.	NULL

Using	NULL
a	NULL
panel	NULL
of	NULL
specific	NULL
antisera	NULL
in	NULL
immunoprecipitation	NULL
assays	NULL
,	NULL
we	NULL
found	NULL
that	NULL
NFATp	NULL
(	NULL
135	NULL
kDa	NULL
)	NULL
is	NULL
constitutively	NULL
expressed	NULL
in	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
while	NULL
synthesis	NULL
of	NULL
NFATe	NULL
(	NULL
predominant	NULL
form	NULL
of	NULL
86	NULL
kDa	NULL
)	NULL
is	NULL
induced	NULL
by	NULL
ionomycin	NULL
treatment	NULL
.	NULL

NFAT4/x	NULL
was	NULL
very	NULL
weakly	NULL
expressed	NULL
in	NULL
unstimulated	NULL
cells	NULL
,	NULL
and	NULL
its	NULL
level	NULL
did	NULL
not	NULL
increase	NULL
upon	NULL
treatment	NULL
with	NULL
activating	NULL
agents	NULL
.	NULL

NFAT3	NULL
protein	NULL
was	NULL
not	NULL
observed	NULL
under	NULL
any	NULL
conditions	NULL
.	NULL

Higher-molecular-weight	NULL
species	NULL
of	NULL
NFAT'¢	NULL
(	NULL
of	NULL
110	NULL
and	NULL
140	NULL
kDa	NULL
)	NULL
were	NULL
also	NULL
detected	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
translation	NULL
of	NULL
NFATe	NULL
mRNA	NULL
apparently	NULL
initiates	NULL
at	NULL
two	NULL
different	NULL
AUG	NULL
codons	NULL
,	NULL
giving	NULL
rise	NULL
to	NULL
proteins	NULL
that	NULL
differ	NULL
in	NULL
size	NULL
by	NULL
36	NULL
amino	NULL
acids	NULL
.	NULL

Additional	NULL
size	NULL
heterogeneity	NULL
of	NULL
both	NULL
NFATc	NULL
and	NULL
NFAT	NULL
p	NULL
results	NULL
from	NULL
phosphorylation	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
ionomycin	NULL
treatment	NULL
,	NULL
exposure	NULL
of	NULL
cells	NULL
to	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
plus	NULL
anti-CD28	NULL
did	NULL
not	NULL
induce	NULL
NFATe	NULL
,	NULL
indicating	NULL
that	NULL
under	NULL
these	NULL
conditions	NULL
,	NULL
interleukin-2	NULL
synthesis	NULL
by	NULL
these	NULL
cells	NULL
is	NULL
apparently	NULL
independent	NULL
of	NULL
NFAT	NULL
'	NULL
c	NULL
.	NULL

In	NULL
DNA	NULL
binding	NULL
assays	NULL
,	NULL
both	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
and	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
resulted	NULL
in	NULL
nuclear	NULL
NFAT	NULL
.	NULL

Surprisingly	NULL
,	NULL
the	NULL
PMA-ionomycin-induced	NULL
synthesis	NULL
of	NULL
NFATc	NULL
that	NULL
was	NULL
detected	NULL
by	NULL
immunoprecipitation	NULL
was	NULL
not	NULL
mirrored	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
assays	NULL
:	NULL
nearly	NULL
all	NULL
of	NULL
the	NULL
activity	NULL
was	NULL
due	NULL
to	NULL
NFATp	NULL
.	NULL

This	NULL
is	NULL
the	NULL
first	NULL
study	NULL
of	NULL
expression	NULL
of	NULL
all	NULL
family	NULL
members	NULL
at	NULL
the	NULL
protein	NULL
level	NULL
in	NULL
normal	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

NFAT	NULL
(	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
)	NULL
is	NULL
implicated	NULL
in	NULL
regulation	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
gene	NULL
transcription	NULL
(	NULL
for	NULL
reviews	NULL
,	NULL
see	NULL
references	NULL
13	NULL
and	NULL
30	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
NFAT-binding	NULL
sites	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
regulatory	NULL
regions	NULL
of	NULL
various	NULL
other	NULL
cytokine	NULL
genes	NULL
,	NULL
including	NULL
the	NULL
IL-4	NULL
(	NULL
3	NULL
,	NULL
33	NULL
,	NULL
38	NULL
)	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
(	NULL
7	NULL
,	NULL
23	NULL
)	NULL
,	NULL
and	NULL
IL-3/granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
4	NULL
,	NULL
22	NULL
)	NULL
genes	NULL
.	NULL

Though	NULL
originally	NULL
found	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
NFAT	NULL
DNA-binding	NULL
activity	NULL
and/or	NULL
protein	NULL
has	NULL
now	NULL
been	NULL
found	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
including	NULL
B	NULL
cells	NULL
(	NULL
2	NULL
,	NULL
40	NULL
,	NULL
41	NULL
,	NULL
45	NULL
)	NULL
,	NULL
mast	NULL
cells	NULL
(	NULL
29	NULL
)	NULL
,	NULL
natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
cells	NULL
(	NULL
1	NULL
)	NULL
,	NULL
and	NULL
a	NULL
neuronal	NULL
cell	NULL
line	NULL
and	NULL
certain	NULL
regions	NULL
of	NULL
the	NULL
brain	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
NFAT	NULL
is	NULL
likely	NULL
to	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
genes	NULL
in	NULL
a	NULL
number	NULL
of	NULL
different	NULL
cell	NULL
types	NULL
.	NULL

To	NULL
date	NULL
,	NULL
cDNAs	NULL
from	NULL
four	NULL
different	NULL
NFAT	NULL
genes	NULL
(	NULL
NFATp	NULL
,	NULL
NFATc	NULL
,	NULL
NFAT3	NULL
,	NULL
and	NULL
NFATA/NFATx	NULL
)	NULL
have	NULL
been	NULL
cloned	NULL
,	NULL
and	NULL
they	NULL
constitute	NULL
a	NULL
related	NULL
but	NULL
quite	NULL
divergent	NULL
family	NULL
(	NULL
9	NULL
,	NULL
11	NULL
,	NULL
18	NULL
,	NULL
21	NULL
,	NULL
24	NULL
,	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

The	NULL
family	NULL
in	NULL
turn	NULL
is	NULL
weakly	NULL
related	NULL
to	NULL
the	NULL
Rel/NF-	NULL
«	NULL
B	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
over	NULL
a	NULL
300-amino-acid	NULL
region	NULL
called	NULL
the	NULL
Rel	NULL
homology	NULL
domain	NULL
(	NULL
RHD	NULL
)	NULL
.	NULL

NFAT	NULL
sequences	NULL
in	NULL
this	NULL
region	NULL
govern	NULL
DNA	NULL
binding	NULL
and	NULL
association	NULL
with	NULL
the	NULL
AP-1	NULL
transcription	NULL
factor	NULL
(	NULL
12	NULL
)	NULL
,	NULL
and	NULL
within	NULL
the	NULL
RHD	NULL
,	NULL
sequence	NULL
conservation	NULL
among	NULL
the	NULL
NFAT	NULL
proteins	NULL
is	NULL
very	NULL
high	NULL
.	NULL

Upstream	NULL
of	NULL
the	NULL
RHD	NULL
,	NULL
NFAT	NULL
proteins	NULL
are	NULL
less	NULL
closely	NULL
related	NULL
,	NULL
but	NULL
they	NULL
do	NULL
share	NULL
several	NULL
serine-	NULL
and	NULL
proline-rich	NULL
segments	NULL
.	NULL

Downstream	NULL
of	NULL
the	NULL
RHD	NULL
,	NULL
NFAT	NULL
proteins	NULL
are	NULL
variable	NULL
in	NULL
length	NULL
and	NULL
in	NULL
sequence	NULL
.	NULL

The	NULL
hallmark	NULL
of	NULL
NFAT	NULL
activity	NULL
is	NULL
its	NULL
inducibility	NULL
by	NULL
agents	NULL
that	NULL
increase	NULL
intracellular	NULL
Ca**	NULL
flux	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
ligands	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
or	NULL
the	NULL
calcium	NULL
ionophore	NULL
ionomycin	NULL
)	NULL
(	NULL
for	NULL
reviews	NULL
,	NULL
see	NULL
references	NULL
5	NULL
and	NULL
35	NULL
)	NULL
.	NULL

The	NULL
increased	NULL
Ca**	NULL
activates	NULL
the	NULL
Ca**/	NULL
calmodulin-dependent	NULL
phosphatase	NULL
calcineurin	NULL
(	NULL
phosphatase	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Molecular	NULL
Basis	NULL
of	NULL
Carcinogenesis	NULL
Laboratory	NULL
,	NULL
ABL-Basic	NULL
Research	NULL
Program	NULL
,	NULL
P.O	NULL
.	NULL

Box	NULL
B	NULL
,	NULL
Frederick	NULL
,	NULL
MD	NULL
21702-1201	NULL
.	NULL

{	NULL
Present	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
Miami	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Miami	NULL
,	NULL
FL	NULL
33136	NULL
.	NULL

2475	NULL
2B	NULL
)	NULL
,	NULL
which	NULL
directly	NULL
or	NULL
indirectly	NULL
results	NULL
in	NULL
dephosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
preexisting	NULL
cytoplasmic	NULL
NFAT	NULL
(	NULL
16	NULL
,	NULL
17	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
process	NULL
involves	NULL
calcineurin	NULL
,	NULL
activation	NULL
of	NULL
NFAT	NULL
is	NULL
inhibited	NULL
by	NULL
the	NULL
immunosuppressive	NULL
drugs	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
FK506	NULL
(	NULL
17	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Until	NULL
recently	NULL
,	NULL
NFAT	NULL
was	NULL
known	NULL
primarily	NULL
through	NULL
DNA	NULL
binding	NULL
assays	NULL
,	NULL
but	NULL
with	NULL
molecular	NULL
cloning	NULL
of	NULL
the	NULL
genes	NULL
,	NULL
development	NULL
of	NULL
reagents	NULL
capable	NULL
of	NULL
recognizing	NULL
specific	NULL
family	NULL
members	NULL
became	NULL
possible	NULL
.	NULL

It	NULL
is	NULL
now	NULL
known	NULL
that	NULL
NFATp	NULL
mRNA	NULL
is	NULL
expressed	NULL
constitutively	NULL
in	NULL
many	NULL
different	NULL
cell	NULL
types	NULL
(	NULL
11	NULL
,	NULL
21	NULL
,	NULL
42	NULL
)	NULL
,	NULL
and	NULL
preexisting	NULL
NFAT	NULL
p	NULL
protein	NULL
translocates	NULL
to	NULL
the	NULL
nucleus	NULL
upon	NULL
stimulation	NULL
of	NULL
the	NULL
cell	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

NFATe	NULL
mRNA	NULL
(	NULL
26	NULL
)	NULL
is	NULL
expressed	NULL
less	NULL
widely	NULL
,	NULL
and	NULL
at	NULL
least	NULL
in	NULL
some	NULL
cell	NULL
types	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
normal	NULL
human	NULL
NK	NULL
cells	NULL
and	NULL
some	NULL
Jurkat	NULL
T-cell	NULL
clones	NULL
)	NULL
,	NULL
it	NULL
is	NULL
not	NULL
expressed	NULL
unless	NULL
cells	NULL
are	NULL
stimulated	NULL
with	NULL
immune	NULL
complexes	NULL
or	NULL
with	NULL
ionomycin	NULL
and	NULL
phorbol	NULL
ester	NULL
(	NULL
1	NULL
,	NULL
21	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Except	NULL
for	NULL
transient	NULL
transfection	NULL
studies	NULL
,	NULL
NFATc	NULL
protein	NULL
has	NULL
not	NULL
been	NULL
described	NULL
.	NULL

NFAT3	NULL
mRNA	NULL
(	NULL
11	NULL
)	NULL
was	NULL
found	NULL
at	NULL
significant	NULL
levels	NULL
in	NULL
several	NULL
organs	NULL
,	NULL
but	NULL
little	NULL
or	NULL
none	NULL
was	NULL
seen	NULL
in	NULL
spleen	NULL
,	NULL
thymus	NULL
,	NULL
or	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
.	NULL

NFAT4	NULL
mRNA	NULL
(	NULL
9	NULL
,	NULL
11	NULL
,	NULL
21	NULL
)	NULL
is	NULL
elevated	NULL
in	NULL
thymus	NULL
,	NULL
but	NULL
is	NULL
also	NULL
detectable	NULL
in	NULL
various	NULL
other	NULL
organs	NULL
.	NULL

In	NULL
Jurkat	NULL
cells	NULL
,	NULL
it	NULL
is	NULL
expressed	NULL
constitutively	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Neither	NULL
NFAT3	NULL
nor	NULL
NFAT4	NULL
protein	NULL
has	NULL
been	NULL
described	NULL
.	NULL

As	NULL
a	NULL
first	NULL
step	NULL
toward	NULL
defining	NULL
specific	NULL
functions	NULL
for	NULL
the	NULL
individual	NULL
NFAT	NULL
proteins	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
expression	NULL
and	NULL
DNA-binding	NULL
properties	NULL
of	NULL
NFAT	NULL
family	NULL
members	NULL
in	NULL
both	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
T	NULL
cells	NULL
.	NULL

Since	NULL
tumor	NULL
cell	NULL
lines	NULL
may	NULL
differ	NULL
in	NULL
significant	NULL
ways	NULL
from	NULL
normal	NULL
nontrans-formed	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
focused	NULL
our	NULL
efforts	NULL
on	NULL
freshly	NULL
isolated	NULL
human	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
(	NULL
PBT	NULL
's	NULL
)	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
and	NULL
tissue	NULL
culture	NULL
.	NULL

Freshly	NULL
purified	NULL
PBTs	NULL
were	NULL
greater	NULL
than	NULL
95	NULL
%	NULL
CD3*	NULL
cells	NULL
.	NULL

Human	NULL
PBTs	NULL
were	NULL
purified	NULL
according	NULL
to	NULL
standard	NULL
procedures	NULL
,	NULL
including	NULL
Ficoll-Hypaque	NULL
centrifugation	NULL
,	NULL
plastic	NULL
adherence	NULL
,	NULL
nylon	NULL
wool	NULL
filtration	NULL
,	NULL
and	NULL
Per-coll	NULL
gradient	NULL
centrifugation	NULL
.	NULL

The	NULL
Jurkat	NULL
human	NULL
T-cell	NULL
line	NULL
(	NULL
clone	NULL
LEI	NULL
)	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
penicillin	NULL
,	NULL
and	NULL
streptomycin	NULL
.	NULL

Phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
;	NULL
Sigma	NULL
)	NULL
was	NULL
used	NULL
at	NULL
5	NULL
to	NULL
10	NULL
ng/ml	NULL
for	NULL
PBTs	NULL
and	NULL
20	NULL
ng/ml	NULL
for	NULL
Jurkat	NULL
cells	NULL
;	NULL
ionomycin	NULL
(	NULL
Boehringer	NULL
2476	NULL
LYAKH	NULL
ET	NULL
AL	NULL
.	NULL

Mannheim	NULL
Biochemicals	NULL
)	NULL
was	NULL
used	NULL
at	NULL
0.25	NULL
to	NULL
1	NULL
pg/ml	NULL
for	NULL
PBTs	NULL
and	NULL
2	NULL
pl/ml	NULL
for	NULL
Jurkat	NULL
cells	NULL
;	NULL
purified	NULL
anti-human	NULL
CD28	NULL
antibody	NULL
(	NULL
anti-CD28	NULL
;	NULL
Pharmingen	NULL
)	NULL
was	NULL
used	NULL
at	NULL
100	NULL
to	NULL
500	NULL
ng/ml	NULL
and	NULL
CsA	NULL
(	NULL
Sandoz	NULL
)	NULL
at	NULL
500	NULL
ng/ml	NULL
.	NULL

Cells	NULL
were	NULL
preincubated	NULL
with	NULL
CsA	NULL
for	NULL
1	NULL
to	NULL
1.5	NULL
h	NULL
before	NULL
addition	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Antisera	NULL
.	NULL

Rabbit	NULL
antisera	NULL
were	NULL
raised	NULL
against	NULL
the	NULL
following	NULL
synthetic	NULL
peptides	NULL
:	NULL
for	NULL
NFATe	NULL
,	NULL
801	NULL
(	NULL
NH	NULL
,	NULL
-CVSPKTTDPEEGFPRGLGA	NULL
[	NULL
residues	NULL
210	NULL
to	NULL
227	NULL
of	NULL
human	NULL
NFATe	NULL
]	NULL
)	NULL
(	NULL
26	NULL
)	NULL
,	NULL
904	NULL
(	NULL
NH	NULL
,	NULL
-KSAEEEHYGYASSNVC	NULL
[	NULL
residues	NULL
38	NULL
to	NULL
52	NULL
of	NULL
human	NULL
NFATc	NULL
]	NULL
)	NULL
,	NULL
905	NULL
(	NULL
NH	NULL
,	NULL
-PSTSFPVPSKFPLC	NULL
[	NULL
residues	NULL
2	NULL
to	NULL
14	NULL
of	NULL
human	NULL
NFATe	NULL
]	NULL
)	NULL
,	NULL
and	NULL
906	NULL
(	NULL
NH	NULL
,	NULL
-CVALKVEPVGEDLGSPP	NULL
[	NULL
residues	NULL
346	NULL
to	NULL
361	NULL
of	NULL
human	NULL
NFATc	NULL
]	NULL
)	NULL
;	NULL
for	NULL
NFATp	NULL
,	NULL
1777	NULL
(	NULL
NH	NULL
,	NULL
-CSPPSGPAYPDDVLDYGLK	NULL
[	NULL
residues	NULL
53	NULL
to	NULL
70	NULL
of	NULL
human	NULL
NFATp	NULL
]	NULL
)	NULL
(	NULL
18	NULL
)	NULL
and	NULL
1616	NULL
(	NULL
NH	NULL
,	NULL
-VPAIKT	NULL
EPSDEYEPSLIC	NULL
[	NULL
residues	NULL
680	NULL
to	NULL
696	NULL
of	NULL
murine	NULL
NFATp	NULL
;	NULL
in	NULL
human	NULL
NFATp	NULL
,	NULL
the	NULL
underlined	NULL
serines	NULL
are	NULL
threonines	NULL
,	NULL
and	NULL
the	NULL
underlined	NULL
glutamic	NULL
acid	NULL
is	NULL
aspartic	NULL
acid	NULL
[	NULL
18	NULL
]	NULL
;	NULL
a	NULL
sequence	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
peptide	NULL
1616	NULL
is	NULL
also	NULL
found	NULL
in	NULL
the	NULL
form	NULL
of	NULL
NFATe	NULL
recently	NULL
described	NULL
by	NULL
Park	NULL
et	NULL
al	NULL
.	NULL

[	NULL
27	NULL
]	NULL
,	NULL
and	NULL
it	NULL
is	NULL
therefore	NULL
possible	NULL
that	NULL
antiserum	NULL
1616	NULL
cross-reacts	NULL
with	NULL
this	NULL
longer	NULL
form	NULL
of	NULL
NFATe	NULL
]	NULL
)	NULL
;	NULL
for	NULL
NFAT3	NULL
,	NULL
890	NULL
(	NULL
NH	NULL
,	NULL
-CDSKVVFIERGPDGKLQWEE	NULL
[	NULL
residues	NULL
614	NULL
to	NULL
632	NULL
of	NULL
human	NULL
NFAT3	NULL
]	NULL
)	NULL
(	NULL
11	NULL
)	NULL
and	NULL
889	NULL
(	NULL
NH	NULL
,	NULL
-GRDLSGFPAPPGEEPPA	NULL
[	NULL
residues	NULL
886	NULL
to	NULL
902	NULL
of	NULL
human	NULL
NFAT3	NULL
]	NULL
)	NULL
;	NULL
for	NULL
NFAT4	NULL
,	NULL
1689	NULL
(	NULL
NH	NULL
,	NULL
-DLQINDPEREFLERPSRDHL	NULL
[	NULL
residues	NULL
130	NULL
to	NULL
149	NULL
of	NULL
human	NULL
NFAT4	NULL
]	NULL
)	NULL
(	NULL
21	NULL
)	NULL
;	NULL
for	NULL
NFATx	NULL
,	NULL
1690	NULL
(	NULL
NH	NULL
,	NULL
-CLPSPESLDLG	NULL
RSDGL	NULL
[	NULL
residues	NULL
1061	NULL
to	NULL
1075	NULL
of	NULL
human	NULL
NFAT	NULL
]	NULL
)	NULL
(	NULL
21	NULL
)	NULL
;	NULL
and	NULL
for	NULL
all	NULL
NFATs	NULL
,	NULL
796	NULL
(	NULL
NH	NULL
,	NULL
-SDIELRKGETDIGRKNTRC	NULL
[	NULL
residues	NULL
542	NULL
to	NULL
559	NULL
of	NULL
human	NULL
NFATc	NULL
]	NULL
)	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Except	NULL
for	NULL
889	NULL
and	NULL
1689	NULL
,	NULL
a	NULL
cysteine	NULL
residue	NULL
was	NULL
added	NULL
at	NULL
the	NULL
N	NULL
or	NULL
C	NULL
terminus	NULL
of	NULL
each	NULL
peptide	NULL
to	NULL
facilitate	NULL
coupling	NULL
to	NULL
hemocyanin	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Monoclonal	NULL
antibody	NULL
7A6	NULL
,	NULL
raised	NULL
against	NULL
recombinant	NULL
NFAT	NULL
,	NULL
was	NULL
a	NULL
gift	NULL
of	NULL
G.	NULL
Crabtree	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
antisera	NULL
1226	NULL
(	NULL
anti-p65	NULL
)	NULL
and	NULL
1141	NULL
(	NULL
anti-p50	NULL
)	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Plasmids	NULL
.	NULL

Full-length	NULL
human	NULL
NFATe	NULL
in	NULL
plasmid	NULL
pBJ5	NULL
(	NULL
p1SH107	NULL
,	NULL
,	NULL
)	NULL
was	NULL
a	NULL
gift	NULL
of	NULL
G.	NULL
Crabtree	NULL
.	NULL

The	NULL
insert	NULL
was	NULL
excised	NULL
with	NULL
BamHI	NULL
and	NULL
cloned	NULL
into	NULL
pRe/CMV	NULL
(	NULL
Invitrogen	NULL
)	NULL
.	NULL

Human	NULL
NFATp	NULL
,	NULL
NFAT3	NULL
,	NULL
and	NULL
NFAT42	NULL
,	NULL
each	NULL
in	NULL
pRep4	NULL
,	NULL
were	NULL
gifts	NULL
of	NULL
T.	NULL
Hoey	NULL
.	NULL

Transfection	NULL
.	NULL

Human	NULL
293	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
10	NULL
%	NULL
/6-cm-diameter	NULL
dish	NULL
.	NULL

Twen-ty-four	NULL
hours	NULL
later	NULL
,	NULL
they	NULL
were	NULL
transfected	NULL
with	NULL
NFAT	NULL
expression	NULL
vectors	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
method	NULL
.	NULL

Oligonucleotides	NULL
.	NULL

Oligonucleotides	NULL
were	NULL
synthesized	NULL
by	NULL
an	NULL
Applied	NULL
Biosys-tems	NULL
synthesizer	NULL
and	NULL
used	NULL
in	NULL
DNA	NULL
binding	NULL
assays	NULL
without	NULL
purification	NULL
.	NULL

For	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
,	NULL
we	NULL
used	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
murine	NULL
IL-4	NULL
NFAT	NULL
site	NULL
(	NULL
5'-ATAAAATTTITCCAATGTAAA-3	NULL
'	NULL
)	NULL
,	NULL
the	NULL
murine	NULL
IL-2	NULL
distal	NULL
NFAT	NULL
site	NULL
(	NULL
5'-GCCCAAAGAGGAAAATTTGTTTCATAC	NULL
A-3	NULL
'	NULL
)	NULL
,	NULL
and	NULL
the	NULL
human	NULL
IL-2	NULL
distal	NULL
NFAT	NULL
site	NULL
(	NULL
5'-TAAGGAGGAAAAACTGT	NULL
TTCATACA-3	NULL
'	NULL
)	NULL
.	NULL

Complementary	NULL
strands	NULL
were	NULL
renatured	NULL
and	NULL
labeled	NULL
with	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Metabolic	NULL
labeling	NULL
.	NULL

PBTs	NULL
(	NULL
5	NULL
X	NULL
10	NULL
%	NULL
/ml	NULL
)	NULL
or	NULL
Jurkat	NULL
cells	NULL
(	NULL
10	NULL
%	NULL
/m1	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
methionine-	NULL
and	NULL
cysteine-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Sigma	NULL
)	NULL
containing	NULL
2	NULL
%	NULL
dialyzed	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
ionomycin	NULL
,	NULL
PMA	NULL
,	NULL
CsA	NULL
,	NULL
anti-CD28	NULL
,	NULL
or	NULL
no	NULL
activating	NULL
agent	NULL
for	NULL
1.5	NULL
to	NULL
3	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
a	NULL
fresh	NULL
aliquot	NULL
of	NULL
the	NULL
same	NULL
medium	NULL
containing	NULL
5	NULL
%	NULL
dialyzed	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
*°SJmethionine	NULL
and	NULL
[	NULL
*°SJcysteine	NULL
(	NULL
each	NULL
at	NULL
100	NULL
.Ci/m	NULL
!	NULL
)	NULL

with	NULL
or	NULL
without	NULL
activating	NULL
agent	NULL
(	NULL
s	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
1.5	NULL
to	NULL
2	NULL
h	NULL
(	NULL
PBTs	NULL
)	NULL
or	NULL
45	NULL
min	NULL
(	NULL
Jurkat	NULL
cells	NULL
)	NULL
.	NULL

At	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
293	NULL
cells	NULL
were	NULL
labeled	NULL
for	NULL
1	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
**Smethionine	NULL
and	NULL
[	NULL
*°SJcysteine	NULL
(	NULL
each	NULL
at	NULL
100	NULL
wCi/m1	NULL
}	NULL
.	NULL

Immunoprecipitations	NULL
.	NULL

To	NULL
reduce	NULL
nonspecific	NULL
background	NULL
,	NULL
immunoprecipitations	NULL
of	NULL
lysates	NULL
from	NULL
PBTs	NULL
and	NULL
Jurkat	NULL
cells	NULL
were	NULL
performed	NULL
in	NULL
two	NULL
cycles	NULL
.	NULL

Whole-cell	NULL
extracts	NULL
were	NULL
precipitated	NULL
(	NULL
with	NULL
or	NULL
without	NULL
prior	NULL
boiling	NULL
)	NULL
,	NULL
and	NULL
precipitates	NULL
were	NULL
washed	NULL
,	NULL
boiled	NULL
,	NULL
and	NULL
reprecipitated	NULL
.	NULL

Two	NULL
different	NULL
lysis	NULL
buffers	NULL
were	NULL
used	NULL
.	NULL

The	NULL
first	NULL
,	NULL
referred	NULL
to	NULL
as	NULL
ELB	NULL
,	NULL
consists	NULL
of	NULL
50	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.0	NULL
)	NULL
,	NULL
250	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
.	NULL

PBTs	NULL
(	NULL
50	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
lysed	NULL
in	NULL
0.3	NULL
to	NULL
1	NULL
ml	NULL
of	NULL
ELB	NULL
,	NULL
and	NULL
insoluble	NULL
material	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
at	NULL
15,000	NULL
x	NULL
g	NULL
for	NULL
15	NULL
min	NULL
.	NULL

Lysis	NULL
buffer	NULL
also	NULL
contained	NULL
phosphatase	NULL
inhibitors	NULL
(	NULL
1	NULL
mM	NULL
sodium	NULL
vanadate	NULL
and	NULL
0.1	NULL
pg	NULL
of	NULL
calyculin	NULL
A	NULL
[	NULL
Bochringer	NULL
Mannheim	NULL
Biochemi-cals	NULL
]	NULL
per	NULL
ml	NULL
)	NULL
and	NULL
protease	NULL
inhibitors	NULL
(	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
aprotinin	NULL
[	NULL
Sigma	NULL
]	NULL
per	NULL
ml	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
leupeptin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
pepstatin	NULL
per	NULL
ml	NULL
)	NULL
or	NULL
protease	NULL
inhibitor	NULL
cocktail	NULL
(	NULL
Bochringer	NULL
Mannheim	NULL
Biochemicals	NULL
)	NULL
diluted	NULL
1:50	NULL
.	NULL

A	NULL
different	NULL
lysis	NULL
procedure	NULL
was	NULL
used	NULL
for	NULL
Jurkat	NULL
cells	NULL
and	NULL
in	NULL
some	NULL
PBT	NULL
experiments	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
in	NULL
ELB	NULL
buffer	NULL
containing	NULL
protease	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
plus	NULL
1	NULL
%	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
,	NULL
1	NULL
%	NULL
B-mercaptocthanol	NULL
,	NULL
and	NULL
0.5	NULL
%	NULL
sodium	NULL
deoxycholate	NULL
(	NULL
ELB-SDS	NULL
)	NULL
.	NULL

Lysates	NULL
were	NULL
boiled	NULL
,	NULL
passed	NULL
through	NULL
a	NULL
22-gauge	NULL
needle	NULL
to	NULL
shear	NULL
the	NULL
DNA	NULL
,	NULL
and	NULL
clarified	NULL
by	NULL
centrifugation	NULL
at	NULL
15,000	NULL
x	NULL
g	NULL
for	NULL
15	NULL
min	NULL
.	NULL

Regardless	NULL
of	NULL
lysis	NULL
procedure	NULL
,	NULL
extracts	NULL
were	NULL
incubated	NULL
overnight	NULL
with	NULL
antiserum	NULL
and	NULL
protein	NULL
A-Sepharose	NULL
(	NULL
Pharmacia	NULL
)	NULL
after	NULL
dilution	NULL
with	NULL
TNT	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
Tris-HCl	NULL
[	NULL
pH	NULL
7.5	NULL
]	NULL
,	NULL
200	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
)	NULL
.	NULL

Precipitates	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
TNT	NULL
buffer	NULL
,	NULL
boiled	NULL
for	NULL
5	NULL
min	NULL
in	NULL
TNT	NULL
containing	NULL
1	NULL
%	NULL
SDS	NULL
,	NULL
and	NULL
centrifuged	NULL
at	NULL
15,000	NULL
x	NULL
g	NULL
for	NULL
3	NULL
min	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
collected	NULL
,	NULL
diluted	NULL
at	NULL
least	NULL
fivefold	NULL
with	NULL
TNT	NULL
buffer	NULL
,	NULL
and	NULL
reprecipitated	NULL
with	NULL
a	NULL
fresh	NULL
aliquot	NULL
of	NULL
the	NULL
same	NULL
antiserum	NULL
.	NULL

The	NULL
second	NULL
cycle	NULL
precipitates	NULL
were	NULL
washed	NULL
and	NULL
analyzed	NULL
by	NULL
10	NULL
%	NULL
Tricine	NULL
SDS-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
PAGE	NULL
)	NULL
(	NULL
Novex	NULL
)	NULL
.	NULL

Transfected	NULL
293	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
ELB	NULL
containing	NULL
protease	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
.	NULL

After	NULL
boiling	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
%	NULL
SDS	NULL
,	NULL
lysates	NULL
were	NULL
diluted	NULL
with	NULL
TNT	NULL
buffer	NULL
,	NULL
and	NULL
aliquots	NULL
(	NULL
1	NULL
to	NULL
3	NULL
%	NULL
of	NULL
the	NULL
total	NULL
)	NULL
were	NULL
immunoprecipitated	NULL
and	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

To-	NULL
q	NULL
905	NULL
904	NULL
801	NULL
906	NULL
796	NULL
NF-ATe	NULL
H	NULL
M	NULL
M	NULL
1777	NULL
1616	NULL
NF-ATp	NULL
I	NULL
M	NULL
890	NULL
889	NULL
NF-AT3	NULL
I-	NULL
|	NULL
1689	NULL
1690	NULL
NF-ATx	NULL
|	NULL
t+	NULL
|	NULL
L_	NULL
RHD	NULL
0	NULL
200	NULL
400	NULL
600	NULL
800	NULL
1000	NULL
Amino	NULL
Acid	NULL
Residue	NULL
Number	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

NFAT	NULL
antisera	NULL
.	NULL

The	NULL
RHDs	NULL
of	NULL
the	NULL
NFAT	NULL
proteins	NULL
are	NULL
aligned	NULL
.	NULL

Boxes	NULL
represent	NULL
peptides	NULL
against	NULL
which	NULL
antisera	NULL
were	NULL
raised	NULL
.	NULL

Peptide	NULL
796	NULL
is	NULL
found	NULL
in	NULL
all	NULL
four	NULL
proteins	NULL
.	NULL

The	NULL
solid	NULL
line	NULL
for	NULL
NFATe	NULL
represents	NULL
one	NULL
of	NULL
the	NULL
two	NULL
splicing	NULL
variants	NULL
that	NULL
have	NULL
been	NULL
described	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
second	NULL
NFATc	NULL
variant	NULL
is	NULL
identical	NULL
except	NULL
for	NULL
an	NULL
additional	NULL
142	NULL
residues	NULL
at	NULL
the	NULL
C	NULL
terminus	NULL
(	NULL
denoted	NULL
by	NULL
the	NULL
dashed	NULL
line	NULL
)	NULL
and	NULL
the	NULL
replacement	NULL
of	NULL
residues	NULL
1	NULL
to	NULL
29	NULL
at	NULL
the	NULL
N	NULL
terminus	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
peptide	NULL
905	NULL
is	NULL
found	NULL
in	NULL
the	NULL
first	NULL
variant	NULL
but	NULL
not	NULL
the	NULL
second	NULL
.	NULL

Several	NULL
3	NULL
'	NULL
splicing	NULL
variants	NULL
of	NULL
NFATp	NULL
have	NULL
been	NULL
found	NULL
(	NULL
18	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Two	NULL
of	NULL
them	NULL
(	NULL
denoted	NULL
by	NULL
the	NULL
solid	NULL
line	NULL
)	NULL
are	NULL
very	NULL
similar	NULL
in	NULL
size	NULL
and	NULL
differ	NULL
only	NULL
at	NULL
their	NULL
extreme	NULL
C	NULL
termini	NULL
.	NULL

The	NULL
third	NULL
is	NULL
considerably	NULL
longer	NULL
(	NULL
denoted	NULL
by	NULL
the	NULL
dashed	NULL
line	NULL
)	NULL
.	NULL

Several	NULL
3	NULL
'	NULL
splice	NULL
variants	NULL
of	NULL
NFAT4	NULL
,	NULL
called	NULL
NFAT42	NULL
,	NULL
-4b	NULL
,	NULL
and	NULL
-4c	NULL
by	NULL
Hoey	NULL
et	NULL
al	NULL
.	NULL

(	NULL
11	NULL
)	NULL
and	NULL
NFAT	NULL
by	NULL
Masuda	NULL
et	NULL
al	NULL
.	NULL

(	NULL
21	NULL
)	NULL
,	NULL
have	NULL
also	NULL
been	NULL
described	NULL
.	NULL

NFAT4a	NULL
and	NULL
-4b	NULL
have	NULL
shorter	NULL
C-terminal	NULL
regions	NULL
than	NULL
NFATx	NULL
.	NULL

NFATA4c	NULL
is	NULL
identical	NULL
to	NULL
NFATx	NULL
except	NULL
at	NULL
the	NULL
extreme	NULL
C	NULL
terminus	NULL
.	NULL

Peptide	NULL
1689	NULL
is	NULL
found	NULL
in	NULL
all	NULL
forms	NULL
,	NULL
but	NULL
peptide	NULL
1690	NULL
is	NULL
unique	NULL
to	NULL
NFAT	NULL
.	NULL

Preparation	NULL
of	NULL
cellular	NULL
extracts	NULL
and	NULL
EMSA	NULL
.	NULL

For	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
cell	NULL
fractions	NULL
,	NULL
PBTs	NULL
(	NULL
25	NULL
X	NULL
10°	NULL
to	NULL
125	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
were	NULL
rinsed	NULL
in	NULL
ice-cold	NULL
hypotonic	NULL
buffer	NULL
(	NULL
HB	NULL
;	NULL
25	NULL
mM	NULL
Tris-HCl	NULL
[	NULL
pH	NULL
7.6	NULL
]	NULL
,	NULL
1	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
5	NULL
mM	NULL
KCI	NULL
)	NULL
and	NULL
lysed	NULL
in	NULL
0.2	NULL
to	NULL
1	NULL
ml	NULL
of	NULL
HB	NULL
containing	NULL
0.05	NULL
%	NULL
Nonidet	NULL
P-40	NULL
.	NULL

After	NULL
vortexing	NULL
,	NULL
the	NULL
lysate	NULL
was	NULL
centrifuged	NULL
at	NULL
500	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
;	NULL
the	NULL
supernatant	NULL
constitutes	NULL
the	NULL
cytoplasmic	NULL
fraction	NULL
.	NULL

After	NULL
being	NULL
washed	NULL
once	NULL
in	NULL
0.5	NULL
to	NULL
2.5	NULL
ml	NULL
of	NULL
HB	NULL
,	NULL
the	NULL
pelleted	NULL
nuclei	NULL
were	NULL
extracted	NULL
with	NULL
30	NULL
to	NULL
150	NULL
pl	NULL
of	NULL
a	NULL
solution	NULL
containing	NULL
50	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
300	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
and	NULL
0.065	NULL
%	NULL
Nonidet	NULL
P-40	NULL
at	NULL
4°C	NULL
for	NULL
30	NULL
min	NULL
with	NULL
agitation	NULL
.	NULL

The	NULL
extract	NULL
was	NULL
centrifuged	NULL
at	NULL
15,000	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
;	NULL
the	NULL
supernatant	NULL
constitutes	NULL
the	NULL
nuclear	NULL
extract	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
determined	NULL
by	NULL
using	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
,	NULL
with	NULL
bovine	NULL
serum	NULL
albumin	NULL
for	NULL
standardization	NULL
.	NULL

For	NULL
EMSA	NULL
,	NULL
the	NULL
binding	NULL
reaction	NULL
mixture	NULL
was	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
80	NULL
mM	NULL
KCI	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
EGTA	NULL
,	NULL
6	NULL
%	NULL
glycerol	NULL
,	NULL
0.5	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
0.5	NULL
pg	NULL
of	NULL
sonicated	NULL
double-stranded	NULL
salmon	NULL
sperm	NULL
DNA	NULL
,	NULL
*°P-labeled	NULL
oligonucleotide	NULL
(	NULL
1	NULL
ng	NULL
;	NULL
~0.5	NULL
X	NULL
10°	NULL
to	NULL
3	NULL
X	NULL
10°	NULL
cpm	NULL
)	NULL
,	NULL
and	NULL
cellular	NULL
lysate	NULL
(	NULL
0.5	NULL
to	NULL
5	NULL
g	NULL
)	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
20	NULL
pl	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
.	NULL

For	NULL
supershift	NULL
analysis	NULL
,	NULL
the	NULL
reaction	NULL
mixture	NULL
minus	NULL
*°P-labeled	NULL
DNA	NULL
was	NULL
preincubated	NULL
with	NULL
1	NULL
pl	NULL
of	NULL
antiserum	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
before	NULL
addition	NULL
of	NULL
the	NULL
*°P-labeled	NULL
DNA	NULL
.	NULL

Products	NULL
were	NULL
analyzed	NULL
on	NULL
6	NULL
%	NULL
DNA	NULL
retardation	NULL
gels	NULL
(	NULL
Novex	NULL
)	NULL
.	NULL

In	NULL
vitro	NULL
phosphatase	NULL
treatment	NULL
.	NULL

Second-cycle	NULL
°S-labeled	NULL
immunoprecipitates	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
TNT	NULL
buffer	NULL
,	NULL
resuspended	NULL
in	NULL
dephosphorylation	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Tris-HCI	NULL
[	NULL
pH	NULL
8.5	NULL
]	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
)	NULL
with	NULL
20	NULL
U	NULL
of	NULL
calf	NULL
intestinal	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
Biochemicals	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
60	NULL
min	NULL
.	NULL

After	NULL
addition	NULL
of	NULL
gel-loading	NULL
buffer	NULL
,	NULL
samples	NULL
were	NULL
boiled	NULL
and	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
(	NULL
Novex	NULL
)	NULL
.	NULL

Human	NULL
293	NULL
cells	NULL
expressing	NULL
transfected	NULL
NFATe	NULL
were	NULL
lysed	NULL
in	NULL
ELB	NULL
buffer	NULL
containing	NULL
1	NULL
%	NULL
SDS	NULL
and	NULL
0.5	NULL
%	NULL
B-mercaptocethanol	NULL
.	NULL

Lysates	NULL
were	NULL
boiled	NULL
,	NULL
diluted	NULL
fivefold	NULL
,	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
anti-NFATc	NULL
801	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
washed	NULL
and	NULL
treated	NULL
with	NULL
alkaline	NULL
phosphatase	NULL
as	NULL
described	NULL
above	NULL
.	NULL

They	NULL
were	NULL
then	NULL
washed	NULL
in	NULL
50	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.0	NULL
)	NULL
and	NULL
incubated	NULL
with	NULL
2	NULL
pg	NULL
of	NULL
calcineurin	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
45	NULL
min	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
.	NULL

After	NULL
a	NULL
final	NULL
wash	NULL
,	NULL
immunoprecipitated	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
,	NULL
and	NULL
subjected	NULL
to	NULL
immu-noblot	NULL
analysis	NULL
.	NULL

Immunoblotting	NULL
.	NULL

Immunoblots	NULL
were	NULL
incubated	NULL
with	NULL
anti-NFATc	NULL
serum	NULL
801	NULL
diluted	NULL
1:1,000	NULL
,	NULL
and	NULL
proteins	NULL
were	NULL
revealed	NULL
with	NULL
the	NULL
Amersham	NULL
ECL	NULL
system	NULL
.	NULL

RESULTS	NULL
NFAT	NULL
antisera	NULL
.	NULL

To	NULL
be	NULL
able	NULL
to	NULL
distinguish	NULL
the	NULL
various	NULL
NFAT	NULL
family	NULL
members	NULL
,	NULL
we	NULL
raised	NULL
antisera	NULL
directed	NULL
against	NULL
synthetic	NULL
peptides	NULL
unique	NULL
to	NULL
each	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
raised	NULL
an	NULL
antiserum	NULL
against	NULL
a	NULL
highly	NULL
conserved	NULL
peptide	NULL
found	NULL
in	NULL
the	NULL
Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
Pda	NULL
.	NULL

Ge	NULL
mocs	NULL
4	NULL
$	NULL
©	NULL
©	NULL
@	NULL
2	NULL
©	NULL
6	NULL
¢	NULL
NFAT	NULL
abs	NULL
:	NULL
%	NULL
*	NULL
®	NULL
%	NULL
%	NULL
``	NULL
0	NULL
%	NULL
)	NULL
%	NULL
%	NULL
\	NULL
M	NULL
o	NULL
NFATp	NULL
-	NULL
»	NULL
|	NULL
``	NULL
Y	NULL
.	NULL

.—97.4	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
abs	NULL
:	NULL
%	NULL
%	NULL
#	NULL
%	NULL
NFATA	NULL
-	NULL
»	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
NFAT	NULL
PROTEINS	NULL
IN	NULL
NORMAL	NULL
HUMAN	NULL
T	NULL
CELLS	NULL
-	NULL
2477	NULL
©	NULL
(	NULL
\	NULL
,	NULL
C	NULL
CAs	NULL
SERA	NULL
(	NULL
NFAT	NULL
abs	NULL
:	NULL
%	NULL
#	NULL
#	NULL
``	NULL
%	NULL
%	NULL
``	NULL
%	NULL
%	NULL
%	NULL
``	NULL
M	NULL
wa	NULL
tn	NULL
D	NULL
jae	NULL
-	NULL
200	NULL
NFAT3	NULL
-	NULL
»	NULL
«	NULL
s	NULL
ans	NULL
ans	NULL
wt	NULL
-97.4	NULL
abs	NULL
:	NULL
NFAT	NULL
-	NULL
H	NULL
wan	NULL
W	NULL
-	NULL
(	NULL
@	NULL
-=	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
Re-IP	NULL
supernatants	NULL
with	NULL
ab	NULL
#	NULL
906	NULL
(	NULL
c	NULL
)	NULL
U	NULL
m	NULL
.	NULL

-	NULL
97.4	NULL
``	NULL
R	NULL
.	NULL

-	NULL
69	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
NFATeCE	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Characterization	NULL
of	NULL
NFAT	NULL
antisera	NULL
.	NULL

Human	NULL
293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
NFATp	NULL
(	NULL
A	NULL
)	NULL
,	NULL
NFAT3	NULL
(	NULL
B	NULL
)	NULL
,	NULL
NFAT4a	NULL
(	NULL
C	NULL
)	NULL
,	NULL
or	NULL
NFATce	NULL
(	NULL
D	NULL
)	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
radioactively	NULL
labeled	NULL
24	NULL
h	NULL
later	NULL
.	NULL

(	NULL
A	NULL
to	NULL
D	NULL
)	NULL
Lysates	NULL
were	NULL
precipitated	NULL
with	NULL
the	NULL
indicated	NULL
antisera	NULL
(	NULL
«	NULL
NFAT	NULL
abs	NULL
)	NULL
,	NULL
and	NULL
precipitates	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

(	NULL
E	NULL
)	NULL
Supernatants	NULL
were	NULL
collected	NULL
from	NULL
samples	NULL
1	NULL
to	NULL
6	NULL
shown	NULL
in	NULL
panel	NULL
D	NULL
and	NULL
were	NULL
reprecipitated	NULL
(	NULL
Re-IP	NULL
)	NULL
with	NULL
serum	NULL
906	NULL
.	NULL

Antiserum	NULL
796	NULL
is	NULL
expected	NULL
to	NULL
recognize	NULL
all	NULL
NFAT	NULL
family	NULL
members	NULL
and	NULL
is	NULL
designated	NULL
796	NULL
(	NULL
pan	NULL
)	NULL
.	NULL

Antisera	NULL
1616	NULL
(	NULL
p	NULL
)	NULL
and	NULL
1777	NULL
(	NULL
p	NULL
)	NULL
are	NULL
directed	NULL
at	NULL
NFATp	NULL
.	NULL

Antisera	NULL
889	NULL
(	NULL
3	NULL
)	NULL
and	NULL
890	NULL
(	NULL
3	NULL
)	NULL
are	NULL
directed	NULL
at	NULL
NFAT3	NULL
.	NULL

Antiserum	NULL
1689	NULL
(	NULL
4	NULL
)	NULL
is	NULL
directed	NULL
at	NULL
all	NULL
forms	NULL
of	NULL
NFAT4	NULL
,	NULL
while	NULL
antiserum	NULL
1690	NULL
(	NULL
x	NULL
)	NULL
should	NULL
recognize	NULL
only	NULL
NFATx	NULL
.	NULL

Antisera	NULL
801	NULL
(	NULL
c	NULL
)	NULL
,	NULL
904	NULL
(	NULL
c	NULL
)	NULL
,	NULL
905	NULL
(	NULL
c	NULL
)	NULL
,	NULL
and	NULL
906	NULL
(	NULL
c	NULL
)	NULL
are	NULL
directed	NULL
at	NULL
NFATc	NULL
.	NULL

An	NULL
asterisk	NULL
indicates	NULL
that	NULL
the	NULL
precipitation	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cognate	NULL
peptide	NULL
.	NULL

Sizes	NULL
are	NULL
indicated	NULL
in	NULL
kilodaltons	NULL
.	NULL

RHD	NULL
.	NULL

This	NULL
antiserum	NULL
,	NULL
796	NULL
,	NULL
recognizes	NULL
all	NULL
of	NULL
the	NULL
known	NULL
family	NULL
members	NULL
.	NULL

Using	NULL
lysates	NULL
from	NULL
human	NULL
293	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
NFATc	NULL
,	NULL
NFATp	NULL
,	NULL
NFAT3	NULL
,	NULL
or	NULL
NFAT4a	NULL
,	NULL
we	NULL
tested	NULL
each	NULL
serum	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
immunoprecipitate	NULL
its	NULL
target	NULL
protein	NULL
in	NULL
a	NULL
specific	NULL
manner	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
antiserum	NULL
796	NULL
recognized	NULL
all	NULL
four	NULL
NFAT	NULL
family	NULL
members	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
to	NULL
C	NULL
,	NULL
lanes	NULL
5	NULL
;	NULL
Fig	NULL
.	NULL

2D	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

This	NULL
binding	NULL
was	NULL
specific	NULL
,	NULL
since	NULL
it	NULL
was	NULL
prevented	NULL
when	NULL
precipitation	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
peptide	NULL
796	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

NFATp	NULL
was	NULL
precipitated	NULL
by	NULL
both	NULL
NFATp	NULL
antisera	NULL
but	NULL
not	NULL
by	NULL
sera	NULL
directed	NULL
at	NULL
NFATc	NULL
,	NULL
NFAT3	NULL
,	NULL
or	NULL
NFAT4	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
NFAT3	NULL
was	NULL
recognized	NULL
by	NULL
both	NULL
NFAT3	NULL
sera	NULL
but	NULL
not	NULL
by	NULL
antisera	NULL
raised	NULL
against	NULL
NFATp	NULL
or	NULL
NFATe	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

NFAT4a	NULL
was	NULL
precipitated	NULL
by	NULL
serum	NULL
1689	NULL
,	NULL
which	NULL
is	NULL
expected	NULL
to	NULL
recognize	NULL
all	NULL
forms	NULL
of	NULL
NFAT4	NULL
,	NULL
but	NULL
not	NULL
by	NULL
serum	NULL
1690	NULL
,	NULL
which	NULL
is	NULL
specific	NULL
for	NULL
the	NULL
longest	NULL
form	NULL
,	NULL
called	NULL
NFAT	NULL
'	NULL
x	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Neither	NULL
NFATp-nor	NULL
NFAT	NULL
'	NULL
c	NULL
antisera	NULL
precipitated	NULL
NFAT4a	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
4	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
all	NULL
NFAT	NULL
antisera	NULL
precipitated	NULL
NFATec	NULL
,	NULL
but	NULL
NFATp-	NULL
and	NULL
NFAT	NULL
'	NULL
x	NULL
sera	NULL
did	NULL
not	NULL
(	NULL
Fig	NULL
.	NULL

2D	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
recognition	NULL
of	NULL
each	NULL
transfected	NULL
protein	NULL
was	NULL
specific	NULL
since	NULL
it	NULL
was	NULL
prevented	NULL
when	NULL
precipitation	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cognate	NULL
peptide	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lane	NULL
7	NULL
;	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
7	NULL
;	NULL
Fig	NULL
.	NULL

2D	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
all	NULL
of	NULL
the	NULL
sera	NULL
specifically	NULL
recognize	NULL
their	NULL
expected	NULL
targets	NULL
and	NULL
do	NULL
not	NULL
cross-react	NULL
with	NULL
other	NULL
family	NULL
members	NULL
.	NULL

We	NULL
also	NULL
tested	NULL
the	NULL
efficiency	NULL
with	NULL
which	NULL
each	NULL
antiserum	NULL
precipitated	NULL
its	NULL
target	NULL
.	NULL

To	NULL
do	NULL
this	NULL
,	NULL
supernatants	NULL
were	NULL
collected	NULL
following	NULL
the	NULL
immunoprecipitations	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
to	NULL
D	NULL
and	NULL
reprecipitated	NULL
with	NULL
one	NULL
of	NULL
the	NULL
NFATp	NULL
sera	NULL
(	NULL
for	NULL
samples	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
,	NULL
with	NULL
one	NULL
of	NULL
the	NULL
NFAT3	NULL
sera	NULL
(	NULL
for	NULL
samples	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
with	NULL
anti-NFAT4a	NULL
serum	NULL
1689	NULL
(	NULL
for	NULL
samples	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
,	NULL
and	NULL
with	NULL
one	NULL
of	NULL
the	NULL
NFATc	NULL
sera	NULL
(	NULL
for	NULL
samples	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2D	NULL
)	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
we	NULL
found	NULL
very	NULL
little	NULL
NFAT	NULL
protein	NULL
in	NULL
the	NULL
supernatants	NULL
.	NULL

An	NULL
example	NULL
of	NULL
the	NULL
results	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2E	NULL
.	NULL

In	NULL
four	NULL
of	NULL
the	NULL
five	NULL
samples	NULL
,	NULL
there	NULL
was	NULL
little	NULL
or	NULL
no	NULL
NFATc	NULL
left	NULL
in	NULL
the	NULL
supernatants	NULL
following	NULL
the	NULL
initial	NULL
precipitation	NULL
by	NULL
either	NULL
the	NULL
pan-NFAT	NULL
serum	NULL
796	NULL
or	NULL
the	NULL
NFATc	NULL
antisera	NULL
(	NULL
Fig	NULL
.	NULL

26	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
and	NULL
5	NULL
)	NULL
.	NULL

The	NULL
only	NULL
exception	NULL
was	NULL
the	NULL
supernatant	NULL
following	NULL
precipitation	NULL
with	NULL
anti-NFATe	NULL
serum	NULL
905	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
substantial	NULL
NFATc	NULL
remained	NULL
and	NULL
was	NULL
precipitated	NULL
in	NULL
the	NULL
second	NULL
step	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

This	NULL
result	NULL
was	NULL
expected	NULL
,	NULL
however	NULL
,	NULL
since	NULL
antiserum	NULL
905	NULL
recognizes	NULL
only	NULL
a	NULL
specific	NULL
small	NULL
fraction	NULL
of	NULL
all	NULL
NFATc	NULL
molecules	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Also	NULL
as	NULL
expected	NULL
,	NULL
NFATe	NULL
was	NULL
found	NULL
in	NULL
the	NULL
supernatant	NULL
when	NULL
the	NULL
first	NULL
precipitation	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
competing	NULL
peptide	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
antisera	NULL
are	NULL
not	NULL
only	NULL
specific	NULL
but	NULL
also	NULL
efficient	NULL
.	NULL

NFAT	NULL
proteins	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
the	NULL
antisera	NULL
recognize	NULL
their	NULL
target	NULL
proteins	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
performed	NULL
immunoprecipitation	NULL
experiments	NULL
with	NULL
Jurkat	NULL
cell	NULL
lysates	NULL
,	NULL
since	NULL
both	NULL
NFATp	NULL
and	NULL
NFATc	NULL
mRNAs	NULL
have	NULL
been	NULL
detected	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
11	NULL
,	NULL
22	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
(	NULL
or	NULL
not	NULL
)	NULL
with	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
P+1	NULL
)	NULL
for	NULL
3	NULL
h	NULL
,	NULL
radioactively	NULL
labeled	NULL
,	NULL
and	NULL
precipitated	NULL
with	NULL
sera	NULL
raised	NULL
against	NULL
NFATp	NULL
,	NULL
NFAT4/x	NULL
,	NULL
or	NULL
NFATc	NULL
.	NULL

As	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
NFATp	NULL
,	NULL
anti-NFATp	NULL
serum	NULL
1777	NULL
recognized	NULL
a	NULL
protein	NULL
of	NULL
about	NULL
135	NULL
kDa	NULL
in	NULL
both	NULL
untreated	NULL
and	NULL
treated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
10	NULL
)	NULL
.	NULL

NFAT4	NULL
antiserum	NULL
1689	NULL
,	NULL
which	NULL
should	NULL
detect	NULL
all	NULL
forms	NULL
of	NULL
NFAT4	NULL
,	NULL
and	NULL
serum	NULL
1690	NULL
,	NULL
which	NULL
should	NULL
detect	NULL
only	NULL
the	NULL
form	NULL
called	NULL
NFAT	NULL
'	NULL
x	NULL
,	NULL
both	NULL
precipitated	NULL
a	NULL
protein	NULL
of	NULL
155	NULL
kDa	NULL
from	NULL
untreated	NULL
cells	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
intensities	NULL
of	NULL
the	NULL
two	NULL
bands	NULL
are	NULL
similar	NULL
,	NULL
and	NULL
since	NULL
the	NULL
size	NULL
of	NULL
the	NULL
protein	NULL
is	NULL
consistent	NULL
with	NULL
that	NULL
predicted	NULL
by	NULL
NFAT	NULL
'	NULL
x	NULL
cDNA	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
NFAT	NULL
is	NULL
the	NULL
predominant	NULL
form	NULL
of	NULL
NFAT4	NULL
expressed	NULL
in	NULL
these	NULL
Jurkat	NULL
cells	NULL
.	NULL

The	NULL
intensities	NULL
of	NULL
the	NULL
NFATp	NULL
and	NULL
NFATx	NULL
bands	NULL
were	NULL
somewhat	NULL
less	NULL
in	NULL
treated	NULL
cells	NULL
(	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
)	NULL
than	NULL
in	NULL
untreated	NULL
cells	NULL
.	NULL

This	NULL
may	NULL
be	NULL
a	NULL
toxic	NULL
effect	NULL
of	NULL
the	NULL
treatment	NULL
and/or	NULL
may	NULL
be	NULL
a	NULL
downregulation	NULL
of	NULL
synthesis	NULL
.	NULL

NFATc	NULL
antiserum	NULL
801	NULL
precipitated	NULL
three	NULL
proteins	NULL
(	NULL
140	NULL
,	NULL
110	NULL
,	NULL
and	NULL
86	NULL
kDa	NULL
)	NULL
from	NULL
untreated	NULL
cells	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
2478	NULL
LYAKH	NULL
ET	NULL
AL	NULL
.	NULL

Un	NULL
P+I	NULL
onFAT	NULL
#	NULL
796	NULL
|	NULL
+*+	NULL
+*	NULL
+	NULL
NFAT	NULL
#	NULL
1777	NULL
+	NULL
+	NULL
cNFAT4	NULL
_	NULL
#	NULL
1689	NULL
+	NULL
anNFAT4	NULL
(	NULL
x	NULL
)	NULL
#	NULL
1690	NULL
+	NULL
+	NULL
#	NULL
801	NULL
+	NULL
+	NULL
kDa	NULL
-	NULL
M	NULL
200-	NULL
ym	NULL
«	NULL
__	NULL
aas	NULL
aas	NULL
waw	NULL
<	NULL
--	NULL
NFAT4	NULL
(	NULL
x	NULL
)	NULL
sae	NULL
wind	NULL
NFAT	NULL
97.4-	NULL
W	NULL
tery	NULL
:	NULL
ENFAT	NULL
’	NULL
;	NULL
<	NULL
+	NULL
W	NULL
<	NULL
--	NULL
so-	NULL
®	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
101112	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Immunoprecipitation	NULL
of	NULL
NFAT	NULL
proteins	NULL
from	NULL
Jurkat	NULL
cells	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
clone	NULL
LEI	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
methionine-	NULL
and	NULL
cysteine-free	NULL
medium	NULL
that	NULL
contained	NULL
P+1I	NULL
or	NULL
no	NULL
activating	NULL
agents	NULL
(	NULL
Un	NULL
)	NULL
for	NULL
2	NULL
h.	NULL
They	NULL
were	NULL
resuspended	NULL
in	NULL
fresh	NULL
aliquots	NULL
of	NULL
the	NULL
same	NULL
medium	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
S	NULL
)	NULL
methionine	NULL
and	NULL
for	NULL
45	NULL
min	NULL
.	NULL

Whole-cell	NULL
lysates	NULL
were	NULL
boiled	NULL
and	NULL
immunoprecipitated	NULL
with	NULL
the	NULL
indicated	NULL
antiserum	NULL
(	NULL
aNFAT	NULL
)	NULL
.	NULL

Precipitates	NULL
were	NULL
washed	NULL
,	NULL
boiled	NULL
,	NULL
and	NULL
reprecipitated	NULL
with	NULL
the	NULL
same	NULL
serum	NULL
.	NULL

These	NULL
second	NULL
precipitates	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

An	NULL
asterisk	NULL
indicates	NULL
that	NULL
the	NULL
precipitation	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cognate	NULL
peptide	NULL
.	NULL

Mobilities	NULL
of	NULL
the	NULL
proteins	NULL
in	NULL
lanes	NULL
2	NULL
to	NULL
7	NULL
can	NULL
not	NULL
be	NULL
compared	NULL
precisely	NULL
with	NULL
those	NULL
in	NULL
lanes	NULL
8	NULL
to	NULL
12	NULL
since	NULL
the	NULL
two	NULL
sets	NULL
were	NULL
analyzed	NULL
on	NULL
different	NULL
gels	NULL
.	NULL

and	NULL
expression	NULL
of	NULL
the	NULL
110-	NULL
and	NULL
86-kDa	NULL
forms	NULL
was	NULL
greatly	NULL
enhanced	NULL
in	NULL
the	NULL
P+I-treated	NULL
cells	NULL
(	NULL
lane	NULL
12	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
of	NULL
the	NULL
inducibility	NULL
of	NULL
NFATe	NULL
(	NULL
22	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
86-kDa	NULL
protein	NULL
corresponds	NULL
to	NULL
the	NULL
NFATe	NULL
cDNA	NULL
cloned	NULL
by	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

(	NULL
26	NULL
)	NULL
and	NULL
is	NULL
the	NULL
same	NULL
size	NULL
as	NULL
seen	NULL
in	NULL
the	NULL
transfected	NULL
293	NULL
cells	NULL
.	NULL

The	NULL
110-kDa	NULL
protein	NULL
is	NULL
predicted	NULL
by	NULL
the	NULL
cDNA	NULL
recently	NULL
reported	NULL
by	NULL
Park	NULL
et	NULL
al	NULL
.	NULL

(	NULL
27	NULL
)	NULL
,	NULL
and	NULL
the	NULL
140-kDa	NULL
protein	NULL
is	NULL
a	NULL
new	NULL
form	NULL
of	NULL
NFATc	NULL
which	NULL
has	NULL
not	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
pan-NFAT	NULL
serum	NULL
796	NULL
precipitated	NULL
each	NULL
of	NULL
the	NULL
NFATp	NULL
,	NULL
NFAT	NULL
'	NULL
c	NULL
,	NULL
and	NULL
NFAT4	NULL
proteins	NULL
,	NULL
as	NULL
expected	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
9	NULL
)	NULL
,	NULL
and	NULL
this	NULL
precipitation	NULL
was	NULL
prevented	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cognate	NULL
peptide	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
NFAT	NULL
antisera	NULL
recognize	NULL
their	NULL
target	NULL
proteins	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

NFATp	NULL
is	NULL
expressed	NULL
in	NULL
untreated	NULL
PBT	NULL
's	NULL
,	NULL
and	NULL
NFATc	NULL
is	NULL
in-ducible	NULL
.	NULL

Purified	NULL
PBTs	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
or	NULL
P+I	NULL
for	NULL
2	NULL
h	NULL
and	NULL
then	NULL
incubated	NULL
in	NULL
medium	NULL
containing	NULL
*°S-labeled	NULL
amino	NULL
acids	NULL
for	NULL
2	NULL
additional	NULL
h	NULL
in	NULL
the	NULL
continued	NULL
presence	NULL
of	NULL
the	NULL
activating	NULL
agents	NULL
.	NULL

Control	NULL
cells	NULL
were	NULL
radioactively	NULL
labeled	NULL
but	NULL
not	NULL
activated	NULL
.	NULL

Whole-cell	NULL
extracts	NULL
were	NULL
immunoprecipitated	NULL
and	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Like	NULL
Jurkat	NULL
cells	NULL
,	NULL
both	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

untreated	NULL
and	NULL
treated	NULL
PBT	NULL
's	NULL
contained	NULL
a	NULL
protein	NULL
of	NULL
135	NULL
kDa	NULL
which	NULL
was	NULL
precipitated	NULL
by	NULL
the	NULL
pan-NFAT	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
7	NULL
,	NULL
and	NULL
11	NULL
)	NULL
.	NULL

Since	NULL
this	NULL
protein	NULL
was	NULL
also	NULL
precipitated	NULL
with	NULL
anti-NFATp	NULL
(	NULL
lanes	NULL
5	NULL
,	NULL
9	NULL
,	NULL
and	NULL
13	NULL
)	NULL
but	NULL
not	NULL
with	NULL
anti-NFATc	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
12	NULL
)	NULL
or	NULL
with	NULL
anti-NFAT	NULL
'	NULL
x	NULL
(	NULL
lanes	NULL
6	NULL
,	NULL
10	NULL
,	NULL
and	NULL
14	NULL
)	NULL
,	NULL
it	NULL
is	NULL
evidently	NULL
NFATp	NULL
.	NULL

Both	NULL
the	NULL
pan-NFAT	NULL
and	NULL
NFATp	NULL
antisera	NULL
also	NULL
precipitated	NULL
a	NULL
second	NULL
protein	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
about	NULL
100,000	NULL
from	NULL
some	NULL
samples	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
5	NULL
)	NULL
.	NULL

We	NULL
have	NULL
not	NULL
yet	NULL
determined	NULL
whether	NULL
this	NULL
protein	NULL
is	NULL
a	NULL
splice	NULL
variant	NULL
of	NULL
NF-ATp	NULL
,	NULL
a	NULL
result	NULL
of	NULL
proteolysis	NULL
of	NULL
NF-ATp	NULL
in	NULL
the	NULL
extracts	NULL
,	NULL
or	NULL
a	NULL
cross-reaction	NULL
of	NULL
the	NULL
serum	NULL
with	NULL
a	NULL
new	NULL
form	NULL
of	NULL
NFATe	NULL
protein	NULL
recently	NULL
described	NULL
by	NULL
Park	NULL
et	NULL
al	NULL
.	NULL

(	NULL
27	NULL
)	NULL
(	NULL
see	NULL
below	NULL
and	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

In	NULL
any	NULL
case	NULL
,	NULL
the	NULL
major	NULL
form	NULL
of	NULL
NFATp	NULL
in	NULL
PBTs	NULL
is	NULL
the	NULL
135-kDa	NULL
protein	NULL
,	NULL
and	NULL
it	NULL
is	NULL
constitutively	NULL
expressed	NULL
.	NULL

Its	NULL
large	NULL
size	NULL
notwithstanding	NULL
,	NULL
this	NULL
protein	NULL
may	NULL
correspond	NULL
to	NULL
a	NULL
mixture	NULL
of	NULL
the	NULL
two	NULL
short	NULL
alternatively	NULL
spliced	NULL
forms	NULL
of	NULL
NFATp	NULL
(	NULL
18	NULL
)	NULL
,	NULL
denoted	NULL
by	NULL
the	NULL
solid	NULL
line	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
(	NULL
see	NULL
Discussion	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
P+1I	NULL
,	NULL
but	NULL
not	NULL
with	NULL
PMA	NULL
alone	NULL
,	NULL
resulted	NULL
in	NULL
a	NULL
prominent	NULL
broadly	NULL
migrating	NULL
band	NULL
with	NULL
an	NULL
average	NULL
molecular	NULL
weight	NULL
of	NULL
86,000	NULL
.	NULL

This	NULL
protein	NULL
was	NULL
precipitated	NULL
by	NULL
the	NULL
pan-NFAT	NULL
serum	NULL
and	NULL
anti-NFATc	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
but	NULL
not	NULL
by	NULL
anti-NFATp	NULL
or	NULL
anti-NFAT	NULL
'	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
NFAT	NULL
'	NULL
c	NULL
,	NULL
whose	NULL
size	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
716-amino-acid	NULL
protein	NULL
predicted	NULL
by	NULL
the	NULL
sequence	NULL
of	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

(	NULL
26	NULL
)	NULL
.	NULL

A	NULL
faint	NULL
band	NULL
at	NULL
about	NULL
the	NULL
same	NULL
position	NULL
as	NULL
NFATp	NULL
was	NULL
produced	NULL
by	NULL
anti-NFATc	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
P+I	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

This	NULL
is	NULL
not	NULL
a	NULL
result	NULL
of	NULL
cross-reaction	NULL
of	NULL
NFATp	NULL
with	NULL
the	NULL
NFATe	NULL
antiserum	NULL
but	NULL
rather	NULL
represents	NULL
the	NULL
novel	NULL
NFAT	NULL
'	NULL
c	NULL
that	NULL
was	NULL
also	NULL
seen	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
;	NULL
see	NULL
below	NULL
)	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
the	NULL
NFATc	NULL
proteins	NULL
was	NULL
inhibited	NULL
by	NULL
CsA	NULL
(	NULL
lanes	NULL
11	NULL
and	NULL
12	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
unlike	NULL
the	NULL
case	NULL
for	NULL
the	NULL
Jurkat	NULL
cells	NULL
,	NULL
there	NULL
is	NULL
little	NULL
or	NULL
no	NULL
NFATe	NULL
in	NULL
untreated	NULL
cells	NULL
,	NULL
but	NULL
it	NULL
is	NULL
strongly	NULL
induced	NULL
by	NULL
treatment	NULL
with	NULL
P+I	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
anti-NFATs	NULL
failed	NULL
to	NULL
detect	NULL
a	NULL
protein	NULL
in	NULL
either	NULL
treated	NULL
or	NULL
untreated	NULL
cells	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
10	NULL
)	NULL
.	NULL

This	NULL
result	NULL
differs	NULL
from	NULL
that	NULL
seen	NULL
with	NULL
Jurkat	NULL
cells	NULL
,	NULL
where	NULL
NFAT	NULL
'	NULL
x	NULL
was	NULL
constitutively	NULL
expressed	NULL
at	NULL
a	NULL
high	NULL
level	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
or	NULL
after	NULL
long	NULL
exposure	NULL
of	NULL
films	NULL
,	NULL
we	NULL
do	NULL
see	NULL
expression	NULL
of	NULL
NFAT	NULL
'	NULL
x	NULL
in	NULL
both	NULL
untreated	NULL
and	NULL
treated	NULL
cells	NULL
.	NULL

For	NULL
example	NULL
,	NULL
Fig	NULL
.	NULL

4B	NULL
shows	NULL
a	NULL
155-kDa	NULL
form	NULL
of	NULL
NFAT4	NULL
in	NULL
ionomycin-treated	NULL
PBT	NULL
's	NULL
.	NULL

The	NULL
protein	NULL
was	NULL
precipitated	NULL
by	NULL
anti-NFAT4	NULL
1689	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
precipitation	NULL
was	NULL
prevented	NULL
by	NULL
competing	NULL
peptide	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Additional	NULL
experiments	NULL
showed	NULL
that	NULL
this	NULL
pro	NULL
A	NULL
Un	NULL
.	NULL

P	NULL
P	NULL
+	NULL
I	NULL
CsA	NULL
+P+	NULL
1	NULL
B	NULL
I	NULL
fou	NULL
1T	NULL
1	NULL
anFAT	NULL
#	NULL
796	NULL
'+	NULL
'	NULL
+	NULL
+	NULL
%	NULL
'	NULL
aNFAT4	NULL
#	NULL
1689	NULL
+	NULL
+	NULL
aNFATe	NULL
#	NULL
801	NULL
+	NULL
+	NULL
aNFATe	NULL
#	NULL
906	NULL
+	NULL
-	NULL
kDa	NULL
aNFATp	NULL
#	NULL
1616	NULL
+	NULL
+	NULL
-	NULL
200	NULL
aNFATx	NULL
#	NULL
1690	NULL
+	NULL
+	NULL
+	NULL
kDa	NULL
NFAT4	NULL
-	NULL
-	NULL
»	NULL
o-	NULL
»	NULL
me	NULL
as	NULL
_	NULL
#	NULL
es	NULL
NFATe	NULL
|	NULL
~*	NULL
-	NULL
97.4	NULL
wn	NULL
.	NULL

tm	NULL
wee	NULL
<	NULL
-	NULL
NFATp	NULL
5+	NULL
--	NULL
»	NULL
97.4	NULL
x	NULL
<	NULL
-	NULL
NFATe	NULL
.	NULL

e	NULL
-	NULL
69	NULL
1	NULL
203	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
1213	NULL
14	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Immunoprecipitation	NULL
of	NULL
NFAT	NULL
proteins	NULL
.	NULL

(	NULL
A	NULL
)	NULL
PBTs	NULL
were	NULL
incubated	NULL
in	NULL
methionine-	NULL
and	NULL
cysteine-free	NULL
medium	NULL
which	NULL
contained	NULL
PMA	NULL
(	NULL
P	NULL
;	NULL
10	NULL
ng/m1	NULL
)	NULL
,	NULL
P+I	NULL
(	NULL
1	NULL
pg/tl	NULL
)	NULL
,	NULL
P+1	NULL
plus	NULL
CsA	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL

1	NULL
)	NULL
,	NULL
or	NULL
no	NULL
activating	NULL
agent	NULL
(	NULL
Un	NULL
)	NULL
for	NULL
2	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
a	NULL
fresh	NULL
aliquot	NULL
of	NULL
the	NULL
same	NULL
medium	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
[	NULL
*SJmethionine	NULL
and	NULL
[	NULL
**SJeysteine	NULL
for	NULL
2	NULL
h.	NULL
Whole-cell	NULL
extracts	NULL
were	NULL
prepared	NULL
in	NULL
ELB	NULL
buffer	NULL
and	NULL
were	NULL
immunoprecipitated	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Precipitates	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

Anti-NFAT	NULL
(	NULL
«	NULL
NFAT	NULL
)	NULL
serum	NULL
796	NULL
recognizes	NULL
all	NULL
NFAT	NULL
proteins	NULL
;	NULL
anti-NFATc	NULL
801	NULL
recognizes	NULL
NFATe	NULL
;	NULL
anti-NFATp	NULL
1616	NULL
recognizes	NULL
NFATp	NULL
;	NULL
and	NULL
anti-NFATx	NULL
1690	NULL
recognizes	NULL
NFAT	NULL
.	NULL

(	NULL
B	NULL
)	NULL
PBTs	NULL
were	NULL
incubated	NULL
in	NULL
methionine-	NULL
and	NULL
cysteine-free	NULL
medium	NULL
for	NULL
2	NULL
h	NULL
,	NULL
the	NULL
last	NULL
30	NULL
min	NULL
of	NULL
which	NULL
included	NULL
ionomycin	NULL
(	NULL
1	NULL
)	NULL
at	NULL
0.5	NULL
pg/ml	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
resuspended	NULL
in	NULL
a	NULL
fresh	NULL
aliquot	NULL
of	NULL
the	NULL
same	NULL
medium	NULL
(	NULL
including	NULL
ionomycin	NULL
)	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
*5S-amino	NULL
acids	NULL
for	NULL
2	NULL
h.	NULL
Whole-cell	NULL
extracts	NULL
were	NULL
prepared	NULL
in	NULL
ELB-SDS	NULL
;	NULL
these	NULL
were	NULL
immunoprecipitated	NULL
and	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

Anti-NFAT4	NULL
1689	NULL
recognizes	NULL
all	NULL
forms	NULL
of	NULL
NFAT4	NULL
;	NULL
anti-NFATc	NULL
906	NULL
recognizes	NULL
NFATc	NULL
.	NULL

An	NULL
asterisk	NULL
indicates	NULL
that	NULL
precipitation	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cognate	NULL
peptide	NULL
.	NULL

Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
tein	NULL
was	NULL
also	NULL
precipitated	NULL
by	NULL
the	NULL
antiserum	NULL
specific	NULL
for	NULL
NFAT	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
expression	NULL
of	NULL
NFAT4/x	NULL
was	NULL
always	NULL
very	NULL
low	NULL
(	NULL
compare	NULL
its	NULL
intensity	NULL
with	NULL
that	NULL
of	NULL
NFATe	NULL
,	NULL
precipitated	NULL
from	NULL
the	NULL
same	NULL
lysate	NULL
[	NULL
lane	NULL
3	NULL
]	NULL
)	NULL
,	NULL
and	NULL
its	NULL
level	NULL
was	NULL
unaffected	NULL
by	NULL
activating	NULL
agents	NULL
.	NULL

No	NULL
shorter	NULL
forms	NULL
of	NULL
NFAT4	NULL
(	NULL
cor-responding	NULL
to	NULL
the	NULL
cDNAs	NULL
called	NULL
NFAT4a	NULL
and	NULL
-4b	NULL
)	NULL
were	NULL
ever	NULL
seen	NULL
in	NULL
PBTs	NULL
or	NULL
Jurkat	NULL
cells	NULL
.	NULL

Finally	NULL
,	NULL
as	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
anti-NFAT3	NULL
antisera	NULL
889	NULL
and	NULL
890	NULL
showed	NULL
no	NULL
reactivity	NULL
with	NULL
extracts	NULL
from	NULL
untreated	NULL
PBTs	NULL
or	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
P+1I	NULL
(	NULL
see	NULL
below	NULL
;	NULL
also	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
results	NULL
demonstrate	NULL
that	NULL
NFATp	NULL
and	NULL
NFAT	NULL
'	NULL
x	NULL
are	NULL
constitutively	NULL
expressed	NULL
in	NULL
PBT	NULL
's	NULL
and	NULL
that	NULL
NFATc	NULL
is	NULL
induced	NULL
by	NULL
ionomycin	NULL
(	NULL
with	NULL
or	NULL
without	NULL
PMA	NULL
)	NULL
in	NULL
a	NULL
CsA-sensitive	NULL
manner	NULL
.	NULL

NFAT3	NULL
was	NULL
not	NULL
detected	NULL
in	NULL
PBT	NULL
's	NULL
.	NULL

It	NULL
may	NULL
be	NULL
useful	NULL
to	NULL
comment	NULL
on	NULL
the	NULL
level	NULL
of	NULL
the	NULL
NFAT	NULL
proteins	NULL
observed	NULL
in	NULL
PBT	NULL
's	NULL
.	NULL

We	NULL
routinely	NULL
used	NULL
lysate	NULL
from	NULL
20	NULL
X	NULL
10°	NULL
to	NULL
80	NULL
x	NULL
10°	NULL
cells	NULL
for	NULL
a	NULL
single	NULL
immunoprecipitation	NULL
,	NULL
and	NULL
films	NULL
were	NULL
exposed	NULL
for	NULL
1	NULL
to	NULL
3	NULL
weeks	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
lysate	NULL
from	NULL
3	NULL
X	NULL
10°	NULL
Jurkat	NULL
cells	NULL
gave	NULL
a	NULL
strong	NULL
signal	NULL
in	NULL
a	NULL
few	NULL
days	NULL
.	NULL

This	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
difference	NULL
in	NULL
size	NULL
of	NULL
PBTs	NULL
and	NULL
Jurkat	NULL
cells	NULL
(	NULL
protein	NULL
content	NULL
per	NULL
cell	NULL
is	NULL
about	NULL
10	NULL
times	NULL
higher	NULL
in	NULL
Jurkat	NULL
cells	NULL
)	NULL
and	NULL
with	NULL
the	NULL
resting	NULL
state	NULL
of	NULL
the	NULL
PBT	NULL
's	NULL
at	NULL
the	NULL
start	NULL
of	NULL
the	NULL
experiments	NULL
.	NULL

The	NULL
relatively	NULL
weak	NULL
signal	NULL
in	NULL
PBT	NULL
's	NULL
is	NULL
not	NULL
due	NULL
to	NULL
limiting	NULL
antibody	NULL
:	NULL
immunoprecipitations	NULL
(	NULL
for	NULL
both	NULL
PBT	NULL
's	NULL
and	NULL
Jurkat	NULL
cells	NULL
)	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
the	NULL
same	NULL
volume	NULL
of	NULL
antiserum	NULL
that	NULL
was	NULL
sufficient	NULL
to	NULL
precipitate	NULL
entirely	NULL
the	NULL
much	NULL
greater	NULL
amount	NULL
of	NULL
NFAT	NULL
proteins	NULL
from	NULL
transiently	NULL
transfected	NULL
cells	NULL
.	NULL

There	NULL
are	NULL
multiple	NULL
forms	NULL
of	NULL
NFATe	NULL
.	NULL

While	NULL
the	NULL
86-kDa	NULL
protein	NULL
was	NULL
always	NULL
the	NULL
most	NULL
prominent	NULL
form	NULL
precipitated	NULL
by	NULL
anti-NFATc	NULL
801	NULL
,	NULL
additional	NULL
bands	NULL
also	NULL
appeared	NULL
.	NULL

As	NULL
noted	NULL
above	NULL
,	NULL
antiserum	NULL
801	NULL
detected	NULL
additional	NULL
proteins	NULL
of	NULL
140	NULL
and	NULL
110	NULL
kDa	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
and	NULL
it	NULL
precipitated	NULL
a	NULL
protein	NULL
of	NULL
140	NULL
kDa	NULL
from	NULL
PBT	NULL
's	NULL
treated	NULL
with	NULL
P+I	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

A	NULL
140-kDa	NULL
protein	NULL
and	NULL
a	NULL
broadly	NULL
migrating	NULL
species	NULL
of	NULL
about	NULL
110	NULL
kDa	NULL
were	NULL
also	NULL
seen	NULL
in	NULL
ionomycin-treated	NULL
PBT	NULL
's	NULL
by	NULL
anti-NFATc	NULL
906	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
whether	NULL
these	NULL
140-	NULL
and	NULL
110-kDa	NULL
proteins	NULL
might	NULL
be	NULL
alternate	NULL
forms	NULL
of	NULL
NFATc	NULL
.	NULL

PBT	NULL
's	NULL
were	NULL
treated	NULL
with	NULL
P+I	NULL
,	NULL
and	NULL
whole-cell	NULL
extracts	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
the	NULL
pan-NFAT	NULL
serum	NULL
796	NULL
,	NULL
with	NULL
anti-NFATc	NULL
801	NULL
,	NULL
or	NULL
with	NULL
three	NULL
additional	NULL
NFATe-specific	NULL
antisera	NULL
.	NULL

Each	NULL
of	NULL
these	NULL
sera	NULL
precipitated	NULL
not	NULL
only	NULL
the	NULL
major	NULL
86-kDa	NULL
form	NULL
of	NULL
NFATc	NULL
but	NULL
also	NULL
two	NULL
additional	NULL
forms	NULL
with	NULL
apparent	NULL
sizes	NULL
of	NULL
140	NULL
and	NULL
110	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
)	NULL
.	NULL

Since	NULL
these	NULL
proteins	NULL
were	NULL
not	NULL
precipitated	NULL
by	NULL
antisera	NULL
directed	NULL
at	NULL
other	NULL
NFAT	NULL
family	NULL
members	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
;	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
10	NULL
;	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
they	NULL
must	NULL
be	NULL
alternate	NULL
forms	NULL
of	NULL
NFATc	NULL
.	NULL

The	NULL
110-kDa	NULL
protein	NULL
is	NULL
presumably	NULL
related	NULL
to	NULL
the	NULL
cDNA	NULL
recently	NULL
reported	NULL
by	NULL
Park	NULL
et	NULL
al	NULL
.	NULL

(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
140-kDa	NULL
form	NULL
has	NULL
not	NULL
been	NULL
described	NULL
previously	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
higher-molecular-weight	NULL
forms	NULL
of	NULL
NFATe	NULL
,	NULL
additional	NULL
heterogeneity	NULL
was	NULL
suggested	NULL
by	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
cDNA	NULL
that	NULL
encodes	NULL
the	NULL
major	NULL
86-kDa	NULL
protein	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
first	NULL
in-frame	NULL
AUG	NULL
codon	NULL
lies	NULL
in	NULL
a	NULL
context	NULL
ill	NULL
suited	NULL
for	NULL
translation	NULL
initiation	NULL
(	NULL
eggAUGc	NULL
)	NULL
,	NULL
while	NULL
the	NULL
context	NULL
of	NULL
the	NULL
second	NULL
is	NULL
closer	NULL
to	NULL
optimal	NULL
(	NULL
accAUGa	NULL
)	NULL
(	NULL
14	NULL
)	NULL
.	NULL

This	NULL
sequence	NULL
predicts	NULL
two	NULL
translated	NULL
products	NULL
:	NULL
a	NULL
minor	NULL
form	NULL
initiated	NULL
at	NULL
the	NULL
first	NULL
AUG	NULL
and	NULL
a	NULL
major	NULL
form	NULL
derived	NULL
from	NULL
the	NULL
second	NULL
.	NULL

These	NULL
two	NULL
proteins	NULL
would	NULL
differ	NULL
in	NULL
size	NULL
by	NULL
the	NULL
36	NULL
amino	NULL
acids	NULL
upstream	NULL
of	NULL
the	NULL
second	NULL
initiation	NULL
codon	NULL
.	NULL

To	NULL
test	NULL
this	NULL
prediction	NULL
,	NULL
we	NULL
used	NULL
an	NULL
antiserum	NULL
(	NULL
anti-NFATc	NULL
905	NULL
)	NULL
directed	NULL
at	NULL
the	NULL
14	NULL
N-terminal	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
longer	NULL
form	NULL
.	NULL

This	NULL
serum	NULL
should	NULL
detect	NULL
only	NULL
the	NULL
longer	NULL
form	NULL
,	NULL
whereas	NULL
a	NULL
serum	NULL
raised	NULL
against	NULL
any	NULL
epitope	NULL
downstream	NULL
of	NULL
the	NULL
second	NULL
methionine	NULL
should	NULL
detect	NULL
both	NULL
forms	NULL
.	NULL

In	NULL
keeping	NULL
with	NULL
this	NULL
prediction	NULL
,	NULL
antiserum	NULL
905	NULL
precipitated	NULL
only	NULL
a	NULL
subset	NULL
of	NULL
the	NULL
heterogeneous	NULL
NFAT	NULL
'	NULL
c	NULL
population	NULL
,	NULL
and	NULL
that	NULL
subset	NULL
con	NULL
NFAT	NULL
PROTEINS	NULL
IN	NULL
NORMAL	NULL
HUMAN	NULL
T	NULL
CELLS	NULL
-	NULL
2479	NULL
A	NULL
P	NULL
+I	NULL
B	NULL
P+	NULL
I	NULL
aNFAT	NULL
#	NULL
796	NULL
``	NULL
+	NULL
Mba	NULL
AM	NULL
aNFATe	NULL
#	NULL
801	NULL
M	NULL
«	NULL
NFAT	NULL
#	NULL
796	NULL
+	NULL
aNFATe	NULL
#	NULL
904	NULL
+	NULL
#	NULL
801	NULL
_	NULL
+	NULL
aNFATe	NULL
#	NULL
905	NULL
+	NULL
#	NULL
905	NULL
+	NULL
kDa	NULL
aNFATe	NULL
#	NULL
906	NULL
+	NULL
my	NULL
ag	NULL
aNFAT3	NULL
#	NULL
890	NULL
+	NULL
Dy	NULL
WB	NULL
-	NULL
200	NULL
@	NULL
-2*°	NULL
-	NULL
nraty	NULL
_-	NULL
i	NULL
-+	NULL
»	NULL
6	NULL
4	NULL
Tm	NULL
.	NULL

|	NULL
4	NULL
i	NULL
NF	NULL
a	NULL
NFATe	NULL
|	NULL
-	NULL
»	NULL
-	NULL
97.4	NULL
if	NULL
|	NULL
Ts	NULL
a	NULL
;	NULL
_	NULL
’	NULL
-	NULL
97.4	NULL
-	NULL
ot	NULL
tha	NULL
)	NULL
tht	NULL
*~	NULL
WB	NULL
Tong	NULL
-s9	NULL
-	NULL
69	NULL
U	NULL
-	NULL
4s	NULL
#	NULL
-as	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

There	NULL
are	NULL
multiple	NULL
forms	NULL
of	NULL
NFATe	NULL
.	NULL

(	NULL
A	NULL
)	NULL
PBTs	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
ionomycin	NULL
(	NULL
1	NULL
mg/ml	NULL
)	NULL
(	NULL
P+1	NULL
)	NULL
for	NULL
1	NULL
h	NULL
in	NULL
methionine-	NULL
and	NULL
cysteine-free	NULL
medium	NULL
and	NULL
then	NULL
radioactively	NULL
labeled	NULL
for	NULL
2	NULL
h	NULL
in	NULL
the	NULL
continued	NULL
presence	NULL
of	NULL
P+I	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
in	NULL
ELB-SDS	NULL
,	NULL
and	NULL
extracts	NULL
were	NULL
immunoprecipitated	NULL
and	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

Anti-NFAT	NULL
(	NULL
«	NULL
NFAT	NULL
)	NULL
796	NULL
recognizes	NULL
all	NULL
NFAT	NULL
proteins	NULL
;	NULL
anti-NFATe	NULL
801	NULL
,	NULL
904	NULL
,	NULL
905	NULL
,	NULL
and	NULL
906	NULL
recognize	NULL
NFATc	NULL
;	NULL
anti-NFAT3	NULL
890	NULL
recognizes	NULL
NFAT3	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
P+I	NULL
for	NULL
2	NULL
h	NULL
and	NULL
then	NULL
radioactively	NULL
labeled	NULL
for	NULL
45	NULL
min	NULL
in	NULL
the	NULL
continued	NULL
presence	NULL
of	NULL
P+I	NULL
.	NULL

Whole-cell	NULL
extracts	NULL
were	NULL
prepared	NULL
in	NULL
ELB-SDS	NULL
,	NULL
and	NULL
immunoprecipitates	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
.	NULL

Antisera	NULL
are	NULL
identified	NULL
above	NULL
.	NULL

sisted	NULL
of	NULL
the	NULL
largest	NULL
molecules	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
;	NULL
compare	NULL
lane	NULL
4	NULL
with	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
.	NULL

This	NULL
was	NULL
true	NULL
for	NULL
all	NULL
three	NULL
sizes	NULL
of	NULL
NFATec	NULL
protein	NULL
.	NULL

The	NULL
same	NULL
result	NULL
was	NULL
obtained	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
;	NULL
compare	NULL
the	NULL
801	NULL
and	NULL
905	NULL
precipitates	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
some	NULL
NFATec	NULL
molecules	NULL
contain	NULL
the	NULL
905	NULL
peptide	NULL
and	NULL
some	NULL
do	NULL
not	NULL
.	NULL

This	NULL
result	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
possibility	NULL
of	NULL
two	NULL
different	NULL
initiation	NULL
codons	NULL
.	NULL

Although	NULL
the	NULL
90-kDa	NULL
protein	NULL
precipitated	NULL
by	NULL
serum	NULL
905	NULL
was	NULL
less	NULL
heterogeneous	NULL
in	NULL
size	NULL
than	NULL
total	NULL
NFATe	NULL
,	NULL
it	NULL
did	NULL
not	NULL
migrate	NULL
as	NULL
a	NULL
sharp	NULL
band	NULL
.	NULL

One	NULL
possible	NULL
explanation	NULL
is	NULL
that	NULL
phosphorylation	NULL
of	NULL
NFATc	NULL
results	NULL
in	NULL
the	NULL
diffuse	NULL
migration	NULL
pattern	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
NFATc	NULL
is	NULL
phosphorylated	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
ionomycin	NULL
alone	NULL
or	NULL
with	NULL
P+I	NULL
,	NULL
NFATe	NULL
immunoprecipitates	NULL
(	NULL
antiserum	NULL
801	NULL
)	NULL
were	NULL
digested	NULL
with	NULL
alkaline	NULL
phosphatase	NULL
before	NULL
electrophoresis	NULL
.	NULL

Digestion	NULL
resulted	NULL
in	NULL
significantly	NULL
increased	NULL
mobility	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
;	NULL
compare	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
with	NULL
lanes	NULL
1	NULL
B	NULL
&	NULL
A	NULL
&	NULL
¢	NULL
§	NULL
$	NULL
~	NULL
a	NULL
IP	NULL
:	NULL
&	NULL
#	NULL
€	NULL
AP	NULL
:	NULL
'	NULL
_	NULL
£-	NULL
+	NULL
AP	NULL
+	NULL
CN	NULL
:	NULL
TTT	NULL
kDa	NULL
kDa	NULL
'—2oo	NULL
-	NULL
200	NULL
_.	NULL
,	NULL
t-	NULL
97.4	NULL
NFAT	NULL
1-2	NULL
-	NULL
WW	NULL
uss	NULL
-	NULL
97.4	NULL
«	NULL
-	NULL
69	NULL
NFATe	NULL
CZ	NULL
hk	NULL
--	NULL
so	NULL
15	NULL
.	NULL

--	NULL
uh	NULL
ough	NULL
ogy	NULL
bah	NULL
(	NULL
)	NULL
_	NULL
46	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
aNFATe	NULL
#	NULL
801	NULL
10	NULL
2	NULL
3	NULL
4	NULL
5	NULL
Probed	NULL
with	NULL
«	NULL
NFATc	NULL
#	NULL
801	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Heterogeneity	NULL
of	NULL
NFATc	NULL
.	NULL

(	NULL
A	NULL
)	NULL
PBTs	NULL
were	NULL
treated	NULL
with	NULL
ionomycin	NULL
(	NULL
1	NULL
)	NULL
(	NULL
0.25	NULL
ug/ml	NULL
)	NULL
or	NULL
PMA	NULL
(	NULL
0.5	NULL
ng/m	NULL
!	NULL
)	NULL

plus	NULL
ionomycin	NULL
(	NULL
P+1	NULL
)	NULL
for	NULL
1	NULL
h	NULL
and	NULL
then	NULL
radioactively	NULL
labeled	NULL
in	NULL
the	NULL
continued	NULL
presence	NULL
of	NULL
the	NULL
activating	NULL
agents	NULL
for	NULL
2	NULL
h.	NULL
Cells	NULL
were	NULL
lysed	NULL
in	NULL
ELB	NULL
,	NULL
and	NULL
whole-cell	NULL
extracts	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-NFATe	NULL
(	NULL
«	NULL
NFATc	NULL
)	NULL
801	NULL
.	NULL

Precipitates	NULL
were	NULL
treated	NULL
with	NULL
calf	NULL
intestinal	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
AP	NULL
)	NULL
(	NULL
+	NULL
)	NULL
or	NULL
were	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
before	NULL
SDS-PAGE	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Human	NULL
293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
plasmid	NULL
expressing	NULL
NFATe	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
ELB-SDS	NULL
,	NULL
and	NULL
the	NULL
lysate	NULL
was	NULL
immunoprecipitated	NULL
(	NULL
IP	NULL
)	NULL
with	NULL
anti-NFATe	NULL
serum	NULL
801	NULL
or	NULL
905	NULL
.	NULL

Precipitates	NULL
were	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
treated	NULL
(	NULL
+	NULL
)	NULL
with	NULL
alkaline	NULL
phosphatase	NULL
(	NULL
AP	NULL
)	NULL
and	NULL
calcineurin	NULL
(	NULL
CN	NULL
)	NULL
.	NULL

The	NULL
digested	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
SDS-PAGE	NULL
,	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
,	NULL
and	NULL
probed	NULL
with	NULL
anti-NFATe	NULL
serum	NULL
801	NULL
.	NULL

IgG	NULL
,	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
;	NULL
Non-sp	NULL
,	NULL
nonspecific	NULL
antiserum	NULL
.	NULL

2480	NULL
LYAKH	NULL
ET	NULL
AL	NULL
.	NULL

and	NULL
3	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
NFAT	NULL
c	NULL
is	NULL
a	NULL
phosphoprotein	NULL
.	NULL

Treatment	NULL
with	NULL
P+1	NULL
resulted	NULL
in	NULL
slower	NULL
migration	NULL
of	NULL
NFATe	NULL
relative	NULL
to	NULL
treatment	NULL
with	NULL
ionomycin	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
protein	NULL
is	NULL
more	NULL
extensively	NULL
phosphorylated	NULL
when	NULL
PMA	NULL
is	NULL
present	NULL
.	NULL

The	NULL
same	NULL
result	NULL
has	NULL
been	NULL
seen	NULL
with	NULL
transiently	NULL
transfected	NULL
NFAT	NULL
'	NULL
c	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
26	NULL
)	NULL
.	NULL

While	NULL
phosphatase	NULL
treatment	NULL
increased	NULL
NFATc	NULL
mobility	NULL
,	NULL
it	NULL
did	NULL
not	NULL
result	NULL
in	NULL
sharp	NULL
bands	NULL
.	NULL

(	NULL
Notice	NULL
that	NULL
the	NULL
140-	NULL
and	NULL
110-kDa	NULL
NFAT	NULL
c	NULL
forms	NULL
are	NULL
practically	NULL
undetectable	NULL
in	NULL
Fig	NULL
.	NULL

6A	NULL
.	NULL

This	NULL
is	NULL
because	NULL
we	NULL
deliberately	NULL
chose	NULL
a	NULL
light	NULL
exposure	NULL
of	NULL
the	NULL
film	NULL
,	NULL
in	NULL
an	NULL
attempt	NULL
to	NULL
resolve	NULL
distinct	NULL
bands	NULL
within	NULL
the	NULL
broadly	NULL
migrating	NULL
86-kDa	NULL
protein	NULL
.	NULL
)	NULL

This	NULL
heterogeneity	NULL
in	NULL
size	NULL
suggested	NULL
that	NULL
digestion	NULL
was	NULL
incomplete	NULL
,	NULL
even	NULL
though	NULL
the	NULL
denatured	NULL
protein	NULL
was	NULL
used	NULL
as	NULL
the	NULL
substrate	NULL
.	NULL

We	NULL
tested	NULL
this	NULL
possibility	NULL
in	NULL
assays	NULL
using	NULL
overexpressed	NULL
NFATc	NULL
derived	NULL
from	NULL
transient	NULL
transfection	NULL
of	NULL
the	NULL
human	NULL
293	NULL
cell	NULL
line	NULL
.	NULL

We	NULL
used	NULL
the	NULL
NFATc	NULL
cDNA	NULL
of	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

(	NULL
26	NULL
)	NULL
,	NULL
which	NULL
encodes	NULL
716	NULL
amino	NULL
acids	NULL
and	NULL
on	NULL
which	NULL
our	NULL
prediction	NULL
of	NULL
two	NULL
initiation	NULL
codons	NULL
is	NULL
based	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
NFATc	NULL
plasmid	NULL
resulted	NULL
in	NULL
a	NULL
protein	NULL
indistinguishable	NULL
in	NULL
size	NULL
and	NULL
heterogeneity	NULL
from	NULL
the	NULL
major	NULL
form	NULL
seen	NULL
in	NULL
PBT	NULL
's	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

As	NULL
with	NULL
the	NULL
PBT	NULL
's	NULL
,	NULL
mobility	NULL
increased	NULL
but	NULL
heterogeneity	NULL
remained	NULL
after	NULL
alkaline	NULL
phosphatase	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
if	NULL
the	NULL
protein	NULL
was	NULL
treated	NULL
with	NULL
both	NULL
alkaline	NULL
phosphatase	NULL
and	NULL
calcineurin	NULL
,	NULL
sharp	NULL
bands	NULL
resulted	NULL
.	NULL

Precipitation	NULL
by	NULL
antiserum	NULL
905	NULL
,	NULL
followed	NULL
by	NULL
digestion	NULL
,	NULL
yielded	NULL
a	NULL
single	NULL
band	NULL
of	NULL
about	NULL
86	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Precipitation	NULL
by	NULL
antiserum	NULL
801	NULL
,	NULL
followed	NULL
by	NULL
digestion	NULL
,	NULL
yielded	NULL
two	NULL
bands	NULL
,	NULL
of	NULL
about	NULL
86	NULL
and	NULL
82	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
there	NULL
are	NULL
two	NULL
forms	NULL
of	NULL
NFAT	NULL
e	NULL
encoded	NULL
by	NULL
the	NULL
cDNA	NULL
in	NULL
the	NULL
expression	NULL
vector	NULL
:	NULL
a	NULL
minor	NULL
longer	NULL
form	NULL
which	NULL
contains	NULL
the	NULL
905	NULL
peptide	NULL
and	NULL
a	NULL
shorter	NULL
major	NULL
form	NULL
which	NULL
does	NULL
not	NULL
.	NULL

The	NULL
difference	NULL
in	NULL
their	NULL
sizes	NULL
agrees	NULL
very	NULL
well	NULL
with	NULL
the	NULL
predicted	NULL
36-amino-acid	NULL
difference	NULL
in	NULL
their	NULL
lengths	NULL
.	NULL

These	NULL
results	NULL
confirm	NULL
the	NULL
use	NULL
of	NULL
two	NULL
different	NULL
initiation	NULL
codons	NULL
in	NULL
translation	NULL
of	NULL
this	NULL
NFATe	NULL
cDNA	NULL
.	NULL

Similarly	NULL
,	NULL
the	NULL
broad	NULL
86-kDa	NULL
band	NULL
seen	NULL
in	NULL
PBT	NULL
's	NULL
and	NULL
Jurkat	NULL
cells	NULL
most	NULL
likely	NULL
results	NULL
from	NULL
a	NULL
combination	NULL
of	NULL
primary	NULL
sequence	NULL
heterogeneity	NULL
and	NULL
phosphorylation-induced	NULL
heterogeneity	NULL
.	NULL

NFATe	NULL
is	NULL
not	NULL
induced	NULL
by	NULL
treatment	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
.	NULL

Results	NULL
presented	NULL
above	NULL
show	NULL
that	NULL
there	NULL
is	NULL
little	NULL
or	NULL
no	NULL
NFATc	NULL
in	NULL
untreated	NULL
PBT	NULL
's	NULL
but	NULL
that	NULL
its	NULL
synthesis	NULL
is	NULL
strongly	NULL
induced	NULL
when	NULL
cells	NULL
are	NULL
treated	NULL
with	NULL
ionomycin	NULL
.	NULL

We	NULL
have	NULL
reported	NULL
previously	NULL
that	NULL
PBT	NULL
's	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
anti-CD28	NULL
contain	NULL
activated	NULL
NFAT	NULL
(	NULL
6	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
NFATc	NULL
is	NULL
induced	NULL
by	NULL
that	NULL
treatment	NULL
as	NULL
well	NULL
,	NULL
we	NULL
radioactively	NULL
labeled	NULL
treated	NULL
cells	NULL
and	NULL
analyzed	NULL
whole-cell	NULL
extracts	NULL
by	NULL
immunopre-cipitation	NULL
.	NULL

We	NULL
found	NULL
little	NULL
or	NULL
no	NULL
induction	NULL
of	NULL
NFATe	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

There	NULL
was	NULL
a	NULL
very	NULL
low	NULL
level	NULL
of	NULL
the	NULL
140-kDa	NULL
NFATc	NULL
detectable	NULL
in	NULL
untreated	NULL
cells	NULL
,	NULL
and	NULL
it	NULL
increased	NULL
only	NULL
very	NULL
slightly	NULL
upon	NULL
treatment	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
incubation	NULL
in	NULL
P+1I	NULL
induced	NULL
NFA¥Te	NULL
strongly	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
and	NULL
the	NULL
induction	NULL
was	NULL
sensitive	NULL
to	NULL
CsA	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

As	NULL
usual	NULL
,	NULL
NFATp	NULL
was	NULL
detectable	NULL
in	NULL
untreated	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
and	NULL
its	NULL
synthesis	NULL
typically	NULL
increased	NULL
somewhat	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
an	NULL
effect	NULL
which	NULL
was	NULL
not	NULL
prevented	NULL
by	NULL
CsA	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

As	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
P+I	NULL
treatment	NULL
usually	NULL
resulted	NULL
in	NULL
a	NULL
lower	NULL
level	NULL
of	NULL
NFAT	NULL
p	NULL
synthesis	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
which	NULL
may	NULL
be	NULL
due	NULL
to	NULL
toxicity	NULL
of	NULL
the	NULL
treatment	NULL
or	NULL
to	NULL
actual	NULL
downregulation	NULL
of	NULL
synthesis	NULL
,	NULL
or	NULL
both	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
at	NULL
least	NULL
partially	NULL
blocked	NULL
by	NULL
CsA	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

Whatever	NULL
the	NULL
cause	NULL
,	NULL
the	NULL
effect	NULL
was	NULL
not	NULL
unique	NULL
to	NULL
NFATp	NULL
,	NULL
as	NULL
synthesis	NULL
of	NULL
the	NULL
NF-kB	NULL
proteins	NULL
p105	NULL
and	NULL
p65	NULL
was	NULL
also	NULL
lower	NULL
in	NULL
the	NULL
cells	NULL
treated	NULL
with	NULL
P+1I	NULL
than	NULL
in	NULL
the	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
anti-CD28	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
.	NULL

Comparison	NULL
with	NULL
NF-kB	NULL
proteins	NULL
is	NULL
also	NULL
useful	NULL
in	NULL
assessing	NULL
the	NULL
level	NULL
of	NULL
NFAT	NULL
in	NULL
PBT	NULL
's	NULL
.	NULL

The	NULL
NFAT	NULL
films	NULL
for	NULL
Fig	NULL
.	NULL

7A	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

&	NULL
§	NULL
)	NULL
!	NULL

~	NULL
©	NULL
a	NULL
x	NULL
ga	NULL
|	NULL
a	NULL
9	NULL
%	NULL
x	NULL
yig	NULL
7	NULL
,	NULL
A	NULL
gia	NULL
)	NULL
o	NULL
a	NULL
<	NULL
G	NULL
kDa	NULL
gee	NULL
-	NULL
200	NULL
-	NULL
»	NULL
tes	NULL
baw	NULL
-	NULL
»	NULL
NFATe	NULL
@	NULL
;	NULL
;	NULL
-	NULL
»	NULL
\n	NULL
WW	NULL
-69	NULL
1	NULL
)	NULL
2	NULL
)	NULL
a	NULL
)	NULL
4a	NULL
)	NULL
5	NULL
)	NULL
8	NULL
aNFATe	NULL
#	NULL
906	NULL
B	NULL
-	NULL
200	NULL
NFATp	NULL
-	NULL
>	NULL
waw	NULL
0B	NULL
0	NULL
--	NULL
#	NULL
#	NULL
t-	NULL
i974	NULL
1	NULL
2	NULL
)	NULL
2a	NULL
)	NULL
)	NULL
a	NULL
)	NULL
5	NULL
)	NULL
6	NULL
aNFATp	NULL
#	NULL
1777	NULL
C	NULL
p105	NULL
-	NULL
»	NULL
p65	NULL
-*	NULL
w	NULL
p50	NULL
-	NULL
»	NULL
**	NULL
sug	NULL
zat	NULL
)	NULL
aNF-xB	NULL
p65	NULL
aNF-xB	NULL
p105/50	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Treatment	NULL
of	NULL
PBTs	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
does	NULL
not	NULL
induce	NULL
synthesis	NULL
of	NULL
NFATc	NULL
.	NULL

PBTs	NULL
were	NULL
incubated	NULL
in	NULL
methionine-	NULL
and	NULL
cysteine-free	NULL
medium	NULL
for	NULL
3.5	NULL
h	NULL
,	NULL
the	NULL
last	NULL
45	NULL
min	NULL
of	NULL
which	NULL
included	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

plus	NULL
anti-CD28	NULL
«	NULL
CD28	NULL
;	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

with	NULL
or	NULL
without	NULL
CsA	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
,	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
0.5	NULL
ug/ml	NULL
)	NULL
with	NULL
or	NULL
without	NULL
CsA	NULL
,	NULL
or	NULL
no	NULL
activating	NULL
agents	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
labeled	NULL
with	NULL
S-amino	NULL
acids	NULL
in	NULL
fresh	NULL
aliquots	NULL
of	NULL
the	NULL
same	NULL
medium	NULL
,	NULL
including	NULL
inducers	NULL
,	NULL
for	NULL
1.5	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
lysed	NULL
in	NULL
ELB-SDS	NULL
.	NULL

Un	NULL
.	NULL

,	NULL
untreated	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-NFATc	NULL
906	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Supernatants	NULL
from	NULL
the	NULL
precipitations	NULL
shown	NULL
in	NULL
panel	NULL
A	NULL
were	NULL
collected	NULL
and	NULL
reprecipitated	NULL
with	NULL
anti-NFATp	NULL
1777	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Supernatants	NULL
from	NULL
the	NULL
precipitations	NULL
shown	NULL
in	NULL
panel	NULL
B	NULL
were	NULL
collected	NULL
and	NULL
reprecipitated	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
anti-p65	NULL
and	NULL
anti-p105/p50	NULL
.	NULL

and	NULL
B	NULL
were	NULL
exposed	NULL
for	NULL
7	NULL
days	NULL
,	NULL
while	NULL
a	NULL
comparable	NULL
signal	NULL
for	NULL
the	NULL
NF-kB	NULL
protein	NULL
p105	NULL
(	NULL
precipitated	NULL
from	NULL
the	NULL
same	NULL
volume	NULL
of	NULL
the	NULL
same	NULL
lysates	NULL
)	NULL
was	NULL
obtained	NULL
on	NULL
overnight	NULL
exposure	NULL
.	NULL

To	NULL
monitor	NULL
the	NULL
effectiveness	NULL
of	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
treatment	NULL
,	NULL
cells	NULL
were	NULL
routinely	NULL
screened	NULL
for	NULL
IL-2	NULL
production	NULL
.	NULL

While	NULL
incubation	NULL
in	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
or	NULL
anti-CD28	NULL
alone	NULL
resulted	NULL
in	NULL
no	NULL
detectable	NULL
IL-2	NULL
,	NULL
treatment	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
gave	NULL
significant	NULL
levels	NULL
,	NULL
as	NULL
did	NULL
P+I	NULL
.	NULL

Typical	NULL
results	NULL
following	NULL
stimulation	NULL
of	NULL
the	NULL
cells	NULL
for	NULL
24	NULL
h	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
untreated	NULL
cells	NULL
,	NULL
<	NULL
1.5	NULL
U	NULL
of	NULL
IL-2/ml	NULL
;	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
,	NULL
329	NULL
U/ml	NULL
;	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
plus	NULL
CsA	NULL
,	NULL
309	NULL
U/ml	NULL
;	NULL
P+1I	NULL
,	NULL
358	NULL
U/ml	NULL
;	NULL
and	NULL
P+I	NULL
plus	NULL
CsA	NULL
,	NULL
<	NULL
1.5	NULL
U/ml	NULL
.	NULL

Thus	NULL
,	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
6	NULL
,	NULL
39	NULL
)	NULL
,	NULL
IL-2	NULL
synthesis	NULL
is	NULL
insensitive	NULL
to	NULL
CsA	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
,	NULL
while	NULL
its	NULL
synthesis	NULL
is	NULL
completely	NULL
CsA-sensitive	NULL
in	NULL
P+I-treated	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
dramatize	NULL
the	NULL
very	NULL
different	NULL
effects	NULL
of	NULL
activating	NULL
cultured	NULL
cells	NULL
with	NULL
P+I	NULL
compared	NULL
with	NULL
activating	NULL
with	NULL
PMA	NULL
+	NULL
anti-CD28	NULL
.	NULL

Both	NULL
treatments	NULL
induce	NULL
synthesis	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
IL-2	NULL
,	NULL
but	NULL
P+1I	NULL
activation	NULL
utilizes	NULL
a	NULL
CsA-sensitive	NULL
pathway	NULL
and	NULL
involves	NULL
a	NULL
strong	NULL
induction	NULL
of	NULL
NFATe	NULL
synthesis	NULL
.	NULL

In	NULL
Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
NFAT	NULL
PROTEINS	NULL
IN	NULL
NORMAL	NULL
HUMAN	NULL
T	NULL
CELLS	NULL
2481	NULL
A	NULL
B	NULL
C	NULL
Nuclear	NULL
P	NULL
+1	NULL
P	NULL
+	NULL
«	NULL
CD28	NULL
Mock	NULL
_	NULL
NFATc	NULL
Cytoplasm	NULL
Extracts	NULL
Tum	NULL
‘	NULL
fmm	NULL
Annen	NULL
»	NULL
aNFAT	NULL
#	NULL
796	NULL
+	NULL
+	NULL
aNFAT	NULL
#	NULL
796	NULL
+	NULL
d	NULL
FY	NULL
aNFATp	NULL
#	NULL
1616	NULL
+	NULL
aNFATp	NULL
#	NULL
1616	NULL
+	NULL
\\\	NULL
¢	NULL
|	NULL
|	NULL
aNFATe	NULL
#	NULL
801	NULL
+	NULL
i	NULL
ame	NULL
aw	NULL
aNFATe	NULL
#	NULL
801	NULL
va	NULL
q	NULL
J	NULL
¢	NULL
eq	NULL
aNFATe	NULL
Mab	NULL
7A6	NULL
+	NULL
+	NULL
aNFATc	NULL
Mab	NULL
7A6	NULL
t	NULL
ob	NULL
tills	NULL
b	NULL
b	NULL
4	NULL
0	NULL
10	NULL
|	NULL
``	NULL
@	NULL
a	NULL
mon	NULL
1	NULL
g~®	NULL
W	NULL
W	NULL
w	NULL
iiw	NULL
“	NULL
t	NULL
“	NULL
5d	NULL
td	NULL
kl	NULL
dd	NULL
dd	NULL
)	NULL
A1	NULL
PUI	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Stimulation	NULL
of	NULL
PBTs	NULL
leads	NULL
to	NULL
nuclear	NULL
NFAT	NULL
DNA-binding	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
PBTs	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
5	NULL
ng/m	NULL
!	NULL
)	NULL

plus	NULL
ionomycin	NULL
(	NULL
0.5	NULL
pg/ml	NULL
)	NULL
(	NULL
P+1	NULL
)	NULL
or	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
(	NULL
P	NULL
+	NULL
«	NULL
€CD28	NULL
)	NULL
for	NULL
4	NULL
h.	NULL
Nuclear	NULL
and	NULL
cytoplasmic	NULL
cell	NULL
fractions	NULL
were	NULL
analyzed	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
bind	NULL
a	NULL
*°P-oligonucleotide	NULL
containing	NULL
the	NULL
NFAT-binding	NULL
site	NULL
from	NULL
the	NULL
murine	NULL
IL-4	NULL
gene	NULL
.	NULL

Un	NULL
,	NULL
untreated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Three	NULL
micrograms	NULL
of	NULL
nuclear	NULL
extract	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
P+1	NULL
and	NULL
5	NULL
pg	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
were	NULL
subjected	NULL
to	NULL
supershift	NULL
analysis	NULL
(	NULL
same	NULL
nuclear	NULL
extracts	NULL
as	NULL
panel	NULL
A	NULL
)	NULL
.	NULL

For	NULL
lanes	NULL
2	NULL
to	NULL
5	NULL
and	NULL
7	NULL
to	NULL
10	NULL
,	NULL
NFAT-specific	NULL
antibodies	NULL
were	NULL
added	NULL
to	NULL
the	NULL
extracts	NULL
prior	NULL
to	NULL
incubation	NULL
with	NULL
the	NULL
P-labeled	NULL
murine	NULL
IL-4	NULL
NFAT	NULL
probe	NULL
.	NULL

Free	NULL
probe	NULL
is	NULL
seen	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
gel	NULL
.	NULL

«	NULL
NFATc	NULL
MAb	NULL
7A6	NULL
,	NULL
monoclonal	NULL
antibody	NULL
7A6	NULL
raised	NULL
against	NULL
NFATc	NULL
.	NULL

(	NULL
C	NULL
)	NULL
293	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
plasmid	NULL
expressing	NULL
NFAT	NULL
,	NULL
and	NULL
whole-cell	NULL
lysates	NULL
were	NULL
prepared	NULL
24	NULL
h	NULL
later	NULL
.	NULL

Aliquots	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
with	NULL
or	NULL
without	NULL
NFAT-specific	NULL
antibodies	NULL
,	NULL
using	NULL
the	NULL
*°P-labeled	NULL
murine	NULL
IL-4	NULL
NFAT	NULL
probe	NULL
.	NULL

In	NULL
lane	NULL
1	NULL
,	NULL
the	NULL
extract	NULL
from	NULL
mock-transfected	NULL
cells	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

contrast	NULL
,	NULL
activation	NULL
by	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
is	NULL
CsA	NULL
insensitive	NULL
and	NULL
does	NULL
not	NULL
result	NULL
in	NULL
induction	NULL
of	NULL
NFATe	NULL
.	NULL

Stimulation	NULL
of	NULL
PBT	NULL
's	NULL
leads	NULL
to	NULL
nuclear	NULL
NFAT	NULL
DNA-binding	NULL
activity	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
effect	NULL
of	NULL
stimulation	NULL
on	NULL
NFAT	NULL
DNA-binding	NULL
activity	NULL
,	NULL
PBTs	NULL
were	NULL
treated	NULL
with	NULL
P+I	NULL
or	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
,	NULL
separated	NULL
into	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
fractions	NULL
,	NULL
and	NULL
subjected	NULL
to	NULL
EMSA	NULL
.	NULL

As	NULL
a	NULL
probe	NULL
,	NULL
we	NULL
used	NULL
the	NULL
murine	NULL
IL-4	NULL
promoter	NULL
NFAT	NULL
-binding	NULL
site	NULL
,	NULL
which	NULL
can	NULL
bind	NULL
NFAT	NULL
alone	NULL
and	NULL
does	NULL
not	NULL
require	NULL
cobinding	NULL
by	NULL
AP-1	NULL
.	NULL

In	NULL
untreated	NULL
cells	NULL
,	NULL
all	NULL
of	NULL
the	NULL
DNA-binding	NULL
activity	NULL
was	NULL
located	NULL
in	NULL
the	NULL
cytoplasm	NULL
,	NULL
as	NULL
expected	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
4	NULL
)	NULL
.	NULL

After	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
P+I	NULL
for	NULL
4	NULL
h	NULL
,	NULL
nearly	NULL
all	NULL
of	NULL
the	NULL
DNA-binding	NULL
activity	NULL
was	NULL
nuclear	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
resulted	NULL
in	NULL
some	NULL
nuclear	NULL
DNA-binding	NULL
activity	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
but	NULL
a	NULL
high	NULL
level	NULL
of	NULL
residual	NULL
cytoplasmic	NULL
NFAT	NULL
as	NULL
well	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
both	NULL
treatments	NULL
result	NULL
in	NULL
NFAT	NULL
trans-location	NULL
,	NULL
but	NULL
P+I	NULL
appears	NULL
to	NULL
be	NULL
more	NULL
efficient	NULL
,	NULL
at	NULL
least	NULL
with	NULL
the	NULL
concentrations	NULL
of	NULL
reagents	NULL
used	NULL
in	NULL
these	NULL
assays	NULL
.	NULL

The	NULL
identities	NULL
of	NULL
the	NULL
nuclear	NULL
NFAT	NULL
proteins	NULL
were	NULL
tested	NULL
by	NULL
supershift	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
the	NULL
immunoprecipitation	NULL
results	NULL
,	NULL
only	NULL
NFATp	NULL
was	NULL
detected	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
.	NULL

With	NULL
the	NULL
murine	NULL
IL-4	NULL
NFAT-binding	NULL
site	NULL
as	NULL
a	NULL
probe	NULL
,	NULL
the	NULL
binding	NULL
activity	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
was	NULL
blocked	NULL
completely	NULL
by	NULL
the	NULL
pan-NFAT	NULL
serum	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
and	NULL
was	NULL
supershifted	NULL
efficiently	NULL
by	NULL
anti-NFATp	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Neither	NULL
anti-NFATc	NULL
801	NULL
nor	NULL
monoclonal	NULL
antibody	NULL
7A6	NULL
(	NULL
raised	NULL
against	NULL
recombinant	NULL
NFATc	NULL
)	NULL
had	NULL
any	NULL
effect	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
both	NULL
NFATp	NULL
and	NULL
NFATe	NULL
were	NULL
readily	NULL
detectable	NULL
in	NULL
cells	NULL
stimulated	NULL
with	NULL
P+1I	NULL
,	NULL
nearly	NULL
all	NULL
of	NULL
the	NULL
DNA-binding	NULL
activity	NULL
was	NULL
due	NULL
to	NULL
NFATp	NULL
.	NULL

This	NULL
was	NULL
true	NULL
regardless	NULL
of	NULL
which	NULL
NFAT	NULL
site	NULL
was	NULL
used	NULL
as	NULL
probe	NULL
and	NULL
of	NULL
which	NULL
anti-NFATe	NULL
serum	NULL
was	NULL
used	NULL
for	NULL
supershifting	NULL
.	NULL

For	NULL
example	NULL
,	NULL
with	NULL
the	NULL
murine	NULL
IL-4	NULL
NFAT	NULL
site	NULL
as	NULL
probe	NULL
,	NULL
the	NULL
pan-NFAT	NULL
serum	NULL
blocked	NULL
binding	NULL
completely	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
,	NULL
lanes	NULL
2	NULL
)	NULL
,	NULL
and	NULL
anti-NFATp	NULL
1616	NULL
supershifted	NULL
almost	NULL
completely	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Anti-NFATe	NULL
801	NULL
and	NULL
monoclonal	NULL
antibody	NULL
7A6	NULL
shifted	NULL
only	NULL
a	NULL
very	NULL
small	NULL
portion	NULL
of	NULL
the	NULL
DNA-binding	NULL
activity	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
.	NULL

With	NULL
the	NULL
distal	NULL
NFAT-binding	NULL
site	NULL
from	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
as	NULL
a	NULL
probe	NULL
,	NULL
the	NULL
pan-	NULL
NFAT	NULL
serum	NULL
again	NULL
blocked	NULL
binding	NULL
completely	NULL
,	NULL
but	NULL
four	NULL
different	NULL
anti-NFATc	NULL
sera	NULL
failed	NULL
to	NULL
shift	NULL
or	NULL
block	NULL
significantly	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
although	NULL
NFATc	NULL
was	NULL
easily	NULL
detectable	NULL
by	NULL
immunoprecipitation	NULL
,	NULL
and	NULL
although	NULL
essentially	NULL
all	NULL
NFAT	NULL
was	NULL
nuclear	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
it	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
represent	NULL
a	NULL
significant	NULL
fraction	NULL
of	NULL
the	NULL
DNA-binding	NULL
activity	NULL
.	NULL

One	NULL
possible	NULL
explanation	NULL
for	NULL
the	NULL
failure	NULL
to	NULL
detect	NULL
DNA	NULL
binding	NULL
by	NULL
NFATe	NULL
is	NULL
that	NULL
the	NULL
NFATe-specific	NULL
antisera	NULL
are	NULL
ineffective	NULL
supershifters	NULL
.	NULL

To	NULL
test	NULL
their	NULL
abilities	NULL
to	NULL
supershift	NULL
or	NULL
inhibit	NULL
an	NULL
NFATe-containing	NULL
DNA-binding	NULL
complex	NULL
,	NULL
293	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
an	NULL
NFAT	NULL
'	NULL
c	NULL
expression	NULL
vector	NULL
,	NULL
and	NULL
whole-cell	NULL
extracts	NULL
were	NULL
analyzed	NULL
in	NULL
EMSA	NULL
with	NULL
the	NULL
murine	NULL
IL-4	NULL
probe	NULL
.	NULL

Overexpressed	NULL
NFAT	NULL
'	NULL
c	NULL
bound	NULL
the	NULL
DNA	NULL
very	NULL
well	NULL
(	NULL
Fig	NULL
.	NULL

8C	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
and	NULL
,	NULL
as	NULL
in	NULL
extracts	NULL
from	NULL
PBT	NULL
's	NULL
,	NULL
the	NULL
pan-	NULL
NFAT	NULL
serum	NULL
blocked	NULL
this	NULL
binding	NULL
completely	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
anti-NFATp	NULL
1616	NULL
was	NULL
unable	NULL
to	NULL
supershift	NULL
the	NULL
complex	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
but	NULL
both	NULL
NFATc	NULL
antibodies	NULL
801	NULL
and	NULL
7A6	NULL
shifted	NULL
it	NULL
completely	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
6	NULL
)	NULL
.	NULL

This	NULL
was	NULL
true	NULL
of	NULL
the	NULL
three	NULL
additional	NULL
NFATc	NULL
peptide	NULL
antisera	NULL
as	NULL
well	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
anti-NFATe	NULL
801	NULL
supershifted	NULL
NFATc	NULL
in	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
P+1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
NFATc	NULL
antisera	NULL
are	NULL
capable	NULL
of	NULL
recognizing	NULL
NFATc	NULL
when	NULL
it	NULL
is	NULL
bound	NULL
to	NULL
DNA	NULL
,	NULL
yet	NULL
they	NULL
detect	NULL
little	NULL
or	NULL
no	NULL
NFATe	NULL
in	NULL
DNA-binding	NULL
complexes	NULL
from	NULL
P+I-treated	NULL
PBT	NULL
's	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
nearly	NULL
all	NULL
of	NULL
the	NULL
DNA-binding	NULL
activity	NULL
in	NULL
such	NULL
cells	NULL
is	NULL
due	NULL
to	NULL
NFATp	NULL
.	NULL

DISCUSSION	NULL
Given	NULL
the	NULL
central	NULL
role	NULL
played	NULL
by	NULL
NFAT	NULL
in	NULL
cytokine	NULL
production	NULL
,	NULL
it	NULL
is	NULL
important	NULL
to	NULL
understand	NULL
its	NULL
regulation	NULL
.	NULL

This	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
a	NULL
complicated	NULL
task	NULL
since	NULL
four	NULL
different	NULL
NFAT	NULL
family	NULL
members	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
and	NULL
at	NULL
least	NULL
three	NULL
of	NULL
these	NULL
have	NULL
alternatively	NULL
spliced	NULL
forms	NULL
(	NULL
11	NULL
,	NULL
21	NULL
,	NULL
24	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Many	NULL
of	NULL
these	NULL
forms	NULL
have	NULL
been	NULL
seen	NULL
only	NULL
at	NULL
the	NULL
cDNA	NULL
level	NULL
in	NULL
libraries	NULL
from	NULL
established	NULL
T-cell	NULL
lines	NULL
.	NULL

To	NULL
determine	NULL
which	NULL
NFAT	NULL
proteins	NULL
are	NULL
present	NULL
in	NULL
normal	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
highly	NULL
purified	NULL
human	NULL
PBT	NULL
's	NULL
in	NULL
immunoprecipitation	NULL
experiments	NULL
.	NULL

In	NULL
untreated	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
major	NULL
form	NULL
of	NULL
NFAT	NULL
was	NULL
NFATp	NULL
,	NULL
2482	NULL
LYAKH	NULL
ET	NULL
AL	NULL
.	NULL

whose	NULL
size	NULL
was	NULL
reduced	NULL
from	NULL
about	NULL
135	NULL
kDa	NULL
to	NULL
about	NULL
125	NULL
kDa	NULL
by	NULL
(	NULL
possibly	NULL
incomplete	NULL
)	NULL
phosphatase	NULL
digestion	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
this	NULL
size	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
longest	NULL
of	NULL
the	NULL
alternatively	NULL
spliced	NULL
cDNAs	NULL
described	NULL
by	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

(	NULL
24	NULL
)	NULL
and	NULL
by	NULL
Luo	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
it	NULL
actually	NULL
corresponds	NULL
to	NULL
the	NULL
two	NULL
shorter	NULL
forms	NULL
(	NULL
denoted	NULL
by	NULL
the	NULL
solid	NULL
line	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
assays	NULL
using	NULL
antisera	NULL
specific	NULL
to	NULL
each	NULL
of	NULL
the	NULL
three	NULL
NFATp	NULL
forms	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
murine	NULL
T	NULL
cells	NULL
express	NULL
predominantly	NULL
the	NULL
two	NULL
short	NULL
forms	NULL
,	NULL
whose	NULL
apparent	NULL
sizes	NULL
are	NULL
about	NULL
140	NULL
kDa	NULL
(	NULL
42	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
when	NULL
cDNA	NULL
encoding	NULL
the	NULL
longest	NULL
form	NULL
(	NULL
containing	NULL
the	NULL
region	NULL
denoted	NULL
by	NULL
the	NULL
dashed	NULL
line	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
was	NULL
transfected	NULL
into	NULL
COS	NULL
cells	NULL
,	NULL
the	NULL
resulting	NULL
protein	NULL
migrated	NULL
significantly	NULL
more	NULL
slowly	NULL
than	NULL
the	NULL
predominant	NULL
form	NULL
in	NULL
murine	NULL
T	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
.	NULL

We	NULL
assume	NULL
that	NULL
,	NULL
like	NULL
the	NULL
mouse	NULL
cells	NULL
,	NULL
human	NULL
T	NULL
cells	NULL
are	NULL
expressing	NULL
the	NULL
shorter	NULL
NFAT	NULL
p	NULL
,	NULL
but	NULL
we	NULL
caution	NULL
that	NULL
we	NULL
do	NULL
not	NULL
yet	NULL
have	NULL
an	NULL
antiserum	NULL
that	NULL
can	NULL
distinguish	NULL
between	NULL
the	NULL
short	NULL
and	NULL
long	NULL
forms	NULL
.	NULL

NFATp	NULL
protein	NULL
of	NULL
approximate	NULL
size	NULL
120	NULL
to	NULL
140	NULL
kDa	NULL
has	NULL
also	NULL
been	NULL
observed	NULL
in	NULL
human	NULL
and	NULL
murine	NULL
T-and	NULL
B-cell	NULL
lines	NULL
(	NULL
25	NULL
,	NULL
28	NULL
,	NULL
34	NULL
)	NULL
,	NULL
in	NULL
human	NULL
NK	NULL
cells	NULL
and	NULL
T-cell	NULL
blasts	NULL
induced	NULL
by	NULL
phytohemagglutinin	NULL
(	NULL
1	NULL
)	NULL
,	NULL
and	NULL
in	NULL
a	NULL
neuronal	NULL
cell	NULL
line	NULL
and	NULL
some	NULL
regions	NULL
of	NULL
the	NULL
nervous	NULL
system	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Unlike	NULL
NFATp	NULL
,	NULL
little	NULL
or	NULL
no	NULL
NFATe	NULL
was	NULL
detected	NULL
in	NULL
untreated	NULL
cells	NULL
.	NULL

(	NULL
Since	NULL
our	NULL
experiments	NULL
involve	NULL
metabolic	NULL
labeling	NULL
of	NULL
cells	NULL
,	NULL
we	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
NFATe	NULL
exists	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
but	NULL
turns	NULL
over	NULL
significantly	NULL
more	NULL
slowly	NULL
than	NULL
does	NULL
NFATp	NULL
.	NULL
)	NULL

However	NULL
,	NULL
like	NULL
NFATe	NULL
mRNA	NULL
(	NULL
1	NULL
,	NULL
21	NULL
,	NULL
26	NULL
)	NULL
,	NULL
we	NULL
found	NULL
that	NULL
NFATc	NULL
protein	NULL
was	NULL
strongly	NULL
induced	NULL
by	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
ionomycin	NULL
,	NULL
with	NULL
or	NULL
without	NULL
PMA	NULL
.	NULL

The	NULL
major	NULL
form	NULL
of	NULL
the	NULL
protein	NULL
produced	NULL
a	NULL
broad	NULL
band	NULL
in	NULL
SDS-PAGE	NULL
,	NULL
with	NULL
an	NULL
average	NULL
size	NULL
of	NULL
about	NULL
86	NULL
kDa	NULL
.	NULL

This	NULL
protein	NULL
has	NULL
not	NULL
been	NULL
found	NULL
previously	NULL
in	NULL
any	NULL
cell	NULL
type	NULL
,	NULL
but	NULL
its	NULL
size	NULL
is	NULL
consistent	NULL
with	NULL
that	NULL
encoded	NULL
by	NULL
the	NULL
NFATc	NULL
cDNA	NULL
described	NULL
by	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

(	NULL
26	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
size	NULL
heterogeneity	NULL
resulted	NULL
from	NULL
two	NULL
factors	NULL
:	NULL
(	NULL
i	NULL
)	NULL
phosphorylation	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
a	NULL
difference	NULL
in	NULL
primary	NULL
sequence	NULL
.	NULL

Transient	NULL
transfection	NULL
of	NULL
NFATc	NULL
cDNA	NULL
resulted	NULL
in	NULL
two	NULL
forms	NULL
of	NULL
the	NULL
protein	NULL
,	NULL
both	NULL
of	NULL
which	NULL
were	NULL
phosphorylated	NULL
.	NULL

These	NULL
two	NULL
forms	NULL
differed	NULL
by	NULL
about	NULL
4	NULL
kDa	NULL
and	NULL
resulted	NULL
from	NULL
initiation	NULL
of	NULL
translation	NULL
at	NULL
two	NULL
different	NULL
AUG	NULL
codons	NULL
.	NULL

Since	NULL
antiserum	NULL
specific	NULL
for	NULL
the	NULL
longer	NULL
form	NULL
also	NULL
recognized	NULL
only	NULL
a	NULL
subset	NULL
of	NULL
NFATc	NULL
in	NULL
PBT	NULL
's	NULL
,	NULL
we	NULL
think	NULL
it	NULL
likely	NULL
that	NULL
the	NULL
two	NULL
initiation	NULL
codons	NULL
are	NULL
used	NULL
there	NULL
as	NULL
well	NULL
.	NULL

Of	NULL
course	NULL
,	NULL
we	NULL
can	NULL
not	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
in	NULL
PBT	NULL
's	NULL
the	NULL
two	NULL
forms	NULL
arise	NULL
through	NULL
alternative	NULL
splicing	NULL
.	NULL

However	NULL
,	NULL
given	NULL
the	NULL
observed	NULL
difference	NULL
in	NULL
their	NULL
sizes	NULL
and	NULL
antibody	NULL
reactivity	NULL
,	NULL
such	NULL
alternatively	NULL
spliced	NULL
forms	NULL
would	NULL
have	NULL
to	NULL
be	NULL
essentially	NULL
the	NULL
same	NULL
as	NULL
those	NULL
translated	NULL
from	NULL
a	NULL
single	NULL
cDNA	NULL
using	NULL
two	NULL
different	NULL
AUG	NULL
codons	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
major	NULL
86-kDa	NULL
NFATce	NULL
,	NULL
denoted	NULL
by	NULL
the	NULL
solid	NULL
line	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
we	NULL
also	NULL
detected	NULL
two	NULL
additional	NULL
forms	NULL
,	NULL
of	NULL
about	NULL
110	NULL
kDa	NULL
and	NULL
140	NULL
kDa	NULL
.	NULL

The	NULL
110-kDa	NULL
protein	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
NFATe	NULL
cDNA	NULL
recently	NULL
described	NULL
by	NULL
Park	NULL
et	NULL
al	NULL
.	NULL

(	NULL
27	NULL
)	NULL
;	NULL
the	NULL
protein	NULL
predicted	NULL
by	NULL
that	NULL
cDNA	NULL
would	NULL
encompass	NULL
both	NULL
the	NULL
solid	NULL
and	NULL
dashed	NULL
lines	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

However	NULL
,	NULL
that	NULL
cDNA	NULL
also	NULL
differs	NULL
at	NULL
its	NULL
extreme	NULL
N	NULL
terminus	NULL
from	NULL
the	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

cDNA	NULL
,	NULL
in	NULL
that	NULL
the	NULL
Park	NULL
et	NULL
al	NULL
.	NULL

clone	NULL
replaces	NULL
the	NULL
first	NULL
42	NULL
residues	NULL
(	NULL
counting	NULL
from	NULL
the	NULL
methionine	NULL
encoded	NULL
by	NULL
the	NULL
first	NULL
,	NULL
weak	NULL
AUG	NULL
codon	NULL
)	NULL
with	NULL
29	NULL
different	NULL
residues	NULL
.	NULL

Antiserum	NULL
905	NULL
would	NULL
not	NULL
recognize	NULL
that	NULL
protein	NULL
.	NULL

Therefore	NULL
,	NULL
since	NULL
antiserum	NULL
905	NULL
does	NULL
recognize	NULL
a	NULL
protein	NULL
of	NULL
about	NULL
110	NULL
kDa	NULL
in	NULL
both	NULL
PBT	NULL
's	NULL
and	NULL
Jurkat	NULL
cells	NULL
,	NULL
there	NULL
may	NULL
be	NULL
three	NULL
NFATc	NULL
proteins	NULL
in	NULL
this	NULL
size	NULL
range	NULL
:	NULL
one	NULL
encoded	NULL
by	NULL
the	NULL
Park	NULL
et	NULL
al	NULL
.	NULL

cDNA	NULL
and	NULL
two	NULL
encoded	NULL
by	NULL
a	NULL
cDNA	NULL
of	NULL
similar	NULL
size	NULL
which	NULL
contains	NULL
the	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

N	NULL
terminus	NULL
.	NULL

No	NULL
cDNA	NULL
corresponding	NULL
to	NULL
the	NULL
140-kDa	NULL
NFATc	NULL
has	NULL
been	NULL
described	NULL
,	NULL
but	NULL
various	NULL
cell	NULL
types	NULL
express	NULL
an	NULL
NFATc	NULL
mRNA	NULL
of	NULL
4.5	NULL
to	NULL
5.2	NULL
kb	NULL
,	NULL
which	NULL
is	NULL
large	NULL
enough	NULL
to	NULL
encode	NULL
it	NULL
(	NULL
11	NULL
,	NULL
21	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Given	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

the	NULL
pattern	NULL
set	NULL
by	NULL
the	NULL
other	NULL
NFAT	NULL
proteins	NULL
,	NULL
it	NULL
seems	NULL
likely	NULL
that	NULL
the	NULL
increased	NULL
length	NULL
of	NULL
the	NULL
140-kDa	NULL
NFATc	NULL
results	NULL
from	NULL
further	NULL
extension	NULL
at	NULL
the	NULL
C	NULL
terminus	NULL
over	NULL
that	NULL
seen	NULL
in	NULL
the	NULL
110-kDa	NULL
protein	NULL
.	NULL

To	NULL
date	NULL
,	NULL
there	NULL
is	NULL
very	NULL
little	NULL
functional	NULL
information	NULL
about	NULL
the	NULL
region	NULL
downstream	NULL
of	NULL
the	NULL
RHD	NULL
in	NULL
the	NULL
NFAT	NULL
proteins	NULL
.	NULL

A	NULL
transactivation	NULL
domain	NULL
has	NULL
been	NULL
found	NULL
in	NULL
this	NULL
region	NULL
in	NULL
NFATp	NULL
(	NULL
19	NULL
)	NULL
,	NULL
but	NULL
the	NULL
86-kDa	NULL
form	NULL
of	NULL
NFATe	NULL
,	NULL
which	NULL
terminates	NULL
at	NULL
essentially	NULL
the	NULL
C	NULL
terminus	NULL
of	NULL
the	NULL
RHD	NULL
,	NULL
can	NULL
activate	NULL
transcription	NULL
in	NULL
reporter	NULL
assays	NULL
(	NULL
6	NULL
,	NULL
11	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Interaction	NULL
of	NULL
NFATp	NULL
with	NULL
AP-1	NULL
appears	NULL
to	NULL
be	NULL
governed	NULL
by	NULL
sequences	NULL
within	NULL
the	NULL
RHD	NULL
(	NULL
12	NULL
,	NULL
25	NULL
)	NULL
,	NULL
and	NULL
interaction	NULL
with	NULL
calcineurin	NULL
apparently	NULL
occurs	NULL
in	NULL
the	NULL
region	NULL
upstream	NULL
of	NULL
the	NULL
RHD	NULL
(	NULL
17	NULL
,	NULL
20	NULL
,	NULL
37	NULL
,	NULL
43	NULL
)	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
difficult	NULL
to	NULL
predict	NULL
what	NULL
functional	NULL
differences	NULL
exist	NULL
among	NULL
the	NULL
various	NULL
NFATc	NULL
forms	NULL
.	NULL

Of	NULL
the	NULL
other	NULL
known	NULL
NFAT	NULL
family	NULL
members	NULL
,	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
detect	NULL
NFAT3	NULL
in	NULL
PBT	NULL
's	NULL
.	NULL

This	NULL
is	NULL
not	NULL
surprising	NULL
,	NULL
since	NULL
NFAT3	NULL
mRNA	NULL
has	NULL
not	NULL
been	NULL
observed	NULL
in	NULL
spleen	NULL
,	NULL
thymus	NULL
,	NULL
or	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
(	NULL
11	NULL
)	NULL
.	NULL

We	NULL
did	NULL
detect	NULL
one	NULL
of	NULL
the	NULL
splice	NULL
variants	NULL
of	NULL
NFAT4	NULL
,	NULL
called	NULL
NFATx	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Like	NULL
NFATp	NULL
,	NULL
it	NULL
was	NULL
present	NULL
in	NULL
untreated	NULL
cells	NULL
but	NULL
at	NULL
a	NULL
very	NULL
low	NULL
level	NULL
that	NULL
did	NULL
not	NULL
change	NULL
upon	NULL
treatment	NULL
of	NULL
the	NULL
cells	NULL
with	NULL
P+1I	NULL
or	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
.	NULL

The	NULL
shorter	NULL
forms	NULL
of	NULL
NFAT4	NULL
,	NULL
called	NULL
NFAT	NULL
4a	NULL
and	NULL
-4b	NULL
,	NULL
were	NULL
not	NULL
detected	NULL
in	NULL
PBT	NULL
's	NULL
or	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
we	NULL
detected	NULL
NFATp	NULL
,	NULL
three	NULL
forms	NULL
of	NULL
NFAT	NULL
,	NULL
and	NULL
NFAT	NULL
in	NULL
PBT	NULL
's	NULL
.	NULL

With	NULL
the	NULL
possible	NULL
exception	NULL
of	NULL
NFAT4c	NULL
(	NULL
whose	NULL
predicted	NULL
size	NULL
should	NULL
be	NULL
indistinguishable	NULL
from	NULL
that	NULL
of	NULL
NFAT	NULL
'	NULL
x	NULL
)	NULL
,	NULL
we	NULL
believe	NULL
that	NULL
this	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
a	NULL
complete	NULL
list	NULL
of	NULL
the	NULL
major	NULL
NFAT	NULL
proteins	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

All	NULL
of	NULL
the	NULL
proteins	NULL
precipitated	NULL
by	NULL
the	NULL
pan-NFAT	NULL
serum	NULL
have	NULL
been	NULL
accounted	NULL
for	NULL
,	NULL
using	NULL
the	NULL
NFATp-	NULL
,	NULL
NFATe-	NULL
,	NULL
and	NULL
NFATx-specific	NULL
sera	NULL
.	NULL

All	NULL
other	NULL
bands	NULL
are	NULL
either	NULL
very	NULL
faint	NULL
,	NULL
not	NULL
reproducible	NULL
,	NULL
or	NULL
clearly	NULL
nonspecific	NULL
.	NULL

Our	NULL
results	NULL
raise	NULL
several	NULL
interesting	NULL
questions	NULL
relevant	NULL
to	NULL
NFAT	NULL
function	NULL
.	NULL

First	NULL
,	NULL
what	NULL
are	NULL
the	NULL
transcription	NULL
factors	NULL
that	NULL
regulate	NULL
NFATc	NULL
synthesis	NULL
?	NULL

We	NULL
observed	NULL
little	NULL
or	NULL
no	NULL
NFATc	NULL
protein	NULL
in	NULL
untreated	NULL
cells	NULL
but	NULL
a	NULL
strong	NULL
CsA-sensitive	NULL
induction	NULL
of	NULL
its	NULL
synthesis	NULL
in	NULL
ionomycin-treated	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
preexisting	NULL
NFATp	NULL
,	NULL
which	NULL
translocates	NULL
to	NULL
the	NULL
nucleus	NULL
following	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
ionomycin	NULL
(	NULL
17	NULL
,	NULL
36	NULL
)	NULL
,	NULL
might	NULL
be	NULL
important	NULL
for	NULL
NFAT	NULL
c	NULL
mRNA	NULL
synthesis	NULL
.	NULL

However	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
recently	NULL
that	NULL
NFATc	NULL
can	NULL
be	NULL
found	NULL
in	NULL
T-cell	NULL
lines	NULL
established	NULL
from	NULL
NFATp-deficient	NULL
mice	NULL
,	NULL
as	NULL
judged	NULL
by	NULL
DNA	NULL
binding	NULL
and	NULL
supershift	NULL
assays	NULL
using	NULL
anti-NFATec	NULL
monoclonal	NULL
antibody	NULL
7A6	NULL
(	NULL
44	NULL
)	NULL
.	NULL

An	NULL
alternative	NULL
regulatory	NULL
mechanism	NULL
might	NULL
involve	NULL
trans-lational	NULL
repression	NULL
of	NULL
a	NULL
low	NULL
level	NULL
of	NULL
preexisting	NULL
NFAT	NULL
c	NULL
mRNA	NULL
in	NULL
untreated	NULL
cells	NULL
and	NULL
Ca**-induced	NULL
derepression	NULL
.	NULL

NFATe	NULL
protein	NULL
itself	NULL
might	NULL
then	NULL
upregulate	NULL
NFATe	NULL
gene	NULL
transcription	NULL
.	NULL

Second	NULL
,	NULL
is	NULL
NFAT	NULL
required	NULL
for	NULL
IL-2	NULL
synthesis	NULL
by	NULL
normal	NULL
human	NULL
PBTs	NULL
?	NULL

Moderate	NULL
levels	NULL
of	NULL
IL-2	NULL
are	NULL
synthesized	NULL
following	NULL
treatment	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
(	NULL
references	NULL
6	NULL
and	NULL
39	NULL
and	NULL
this	NULL
report	NULL
)	NULL
,	NULL
and	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
only	NULL
NFATp	NULL
and	NULL
trace	NULL
levels	NULL
of	NULL
NFAT	NULL
'	NULL
x	NULL
were	NULL
detectable	NULL
under	NULL
these	NULL
conditions	NULL
.	NULL

Yet	NULL
IL-2	NULL
synthesis	NULL
is	NULL
normal	NULL
in	NULL
NFATp-negative	NULL
cells	NULL
treated	NULL
with	NULL
concanavalin	NULL
A	NULL
or	NULL
anti-CD3	NULL
(	NULL
10	NULL
,	NULL
44	NULL
)	NULL
,	NULL
suggesting	NULL
either	NULL
that	NULL
NFATp	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
IL-2	NULL
synthesis	NULL
or	NULL
that	NULL
the	NULL
normal	NULL
role	NULL
of	NULL
NFATp	NULL
can	NULL
be	NULL
filled	NULL
by	NULL
another	NULL
NFAT	NULL
family	NULL
member	NULL
in	NULL
the	NULL
deficient	NULL
cells	NULL
.	NULL

It	NULL
would	NULL
be	NULL
interesting	NULL
to	NULL
know	NULL
whether	NULL
NFATp-negative	NULL
T	NULL
cells	NULL
can	NULL
synthesize	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
treatment	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
.	NULL

Third	NULL
,	NULL
what	NULL
triggers	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFAT	NULL
p	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
?	NULL

Normally	NULL
,	NULL
NFAT	NULL
translocation	NULL
requires	NULL
the	NULL
Ca**-induced	NULL
activation	NULL
of	NULL
calcineurin	NULL
,	NULL
which	NULL
can	NULL
be	NULL
brought	NULL
about	NULL
by	NULL
ligation	NULL
of	NULL
CD3	NULL
or	NULL
by	NULL
treatment	NULL
with	NULL
ionomycin	NULL
.	NULL

Since	NULL
it	NULL
involves	NULL
calcineurin	NULL
,	NULL
this	NULL
pathway	NULL
is	NULL
CsA	NULL
sensitive	NULL
.	NULL

However	NULL
,	NULL
PMA-anti-CD28-induced	NULL
Vor	NULL
.	NULL

17	NULL
,	NULL
1997	NULL
translocation	NULL
of	NULL
NFATp	NULL
is	NULL
CsA	NULL
resistant	NULL
,	NULL
as	NULL
is	NULL
IL-2	NULL
synthesis	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
references	NULL
6	NULL
and	NULL
39	NULL
and	NULL
this	NULL
report	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
either	NULL
that	NULL
PMA	NULL
plus	NULL
anti-CD28	NULL
induces	NULL
a	NULL
different	NULL
Ca**	NULL
-independent	NULL
phosphatase	NULL
that	NULL
can	NULL
act	NULL
on	NULL
NFATp	NULL
or	NULL
that	NULL
there	NULL
are	NULL
ways	NULL
other	NULL
than	NULL
dephosphorylation	NULL
to	NULL
effect	NULL
NFATp	NULL
translocation	NULL
.	NULL

Fourth	NULL
,	NULL
why	NULL
were	NULL
we	NULL
unable	NULL
to	NULL
detect	NULL
significant	NULL
DNA	NULL
binding	NULL
by	NULL
NFATc	NULL
in	NULL
extracts	NULL
from	NULL
P+I-treated	NULL
cells	NULL
?	NULL

Judging	NULL
from	NULL
the	NULL
immunoprecipitation	NULL
experiments	NULL
,	NULL
there	NULL
is	NULL
as	NULL
much	NULL
NFATc	NULL
as	NULL
NFATp	NULL
in	NULL
those	NULL
cells	NULL
,	NULL
yet	NULL
nearly	NULL
all	NULL
of	NULL
the	NULL
DNA-binding	NULL
activity	NULL
was	NULL
due	NULL
to	NULL
NFATp	NULL
.	NULL

This	NULL
was	NULL
true	NULL
regardless	NULL
of	NULL
which	NULL
of	NULL
three	NULL
different	NULL
NFAT-binding	NULL
sites	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

However	NULL
,	NULL
transfected	NULL
NFATc	NULL
was	NULL
able	NULL
to	NULL
bind	NULL
DNA	NULL
,	NULL
and	NULL
the	NULL
NFATc	NULL
antisera	NULL
were	NULL
able	NULL
to	NULL
supershift	NULL
the	NULL
complex	NULL
.	NULL

Similarly	NULL
,	NULL
NFATc	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
DNA-binding	NULL
complex	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
P+1I	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
we	NULL
would	NULL
have	NULL
detected	NULL
NFATe	NULL
in	NULL
the	NULL
T-cell	NULL
extracts	NULL
if	NULL
it	NULL
constituted	NULL
a	NULL
significant	NULL
fraction	NULL
of	NULL
the	NULL
total	NULL
binding	NULL
activity	NULL
.	NULL

Therefore	NULL
,	NULL
perhaps	NULL
the	NULL
relative	NULL
intensities	NULL
of	NULL
the	NULL
NFATp	NULL
and	NULL
NFATc	NULL
bands	NULL
in	NULL
the	NULL
immunoprecipitation	NULL
experiments	NULL
do	NULL
not	NULL
accurately	NULL
reflect	NULL
the	NULL
absolute	NULL
levels	NULL
of	NULL
the	NULL
two	NULL
proteins	NULL
,	NULL
and	NULL
we	NULL
have	NULL
considerably	NULL
overestimated	NULL
the	NULL
amount	NULL
of	NULL
NFATe	NULL
present	NULL
in	NULL
the	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
a	NULL
similar	NULL
experiment	NULL
,	NULL
Aram-buru	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1	NULL
)	NULL
found	NULL
that	NULL
CD16	NULL
ligand	NULL
binding	NULL
or	NULL
P+1	NULL
induced	NULL
NFATc	NULL
mRNA	NULL
synthesis	NULL
in	NULL
human	NULL
NK	NULL
cells	NULL
,	NULL
but	NULL
they	NULL
were	NULL
also	NULL
unable	NULL
to	NULL
detect	NULL
DNA	NULL
binding	NULL
by	NULL
NFATc	NULL
protein	NULL
in	NULL
nuclear	NULL
extracts	NULL
.	NULL

DNA	NULL
binding	NULL
by	NULL
NFAT	NULL
'	NULL
c	NULL
was	NULL
detected	NULL
after	NULL
CD3	NULL
ligation	NULL
in	NULL
murine	NULL
T	NULL
cells	NULL
but	NULL
not	NULL
after	NULL
treatment	NULL
with	NULL
ionomycin	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
does	NULL
PMA-induced	NULL
phosphorylation	NULL
of	NULL
NFAT	NULL
have	NULL
functional	NULL
consequences	NULL
?	NULL

NFAT	NULL
c	NULL
migrated	NULL
more	NULL
slowly	NULL
in	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
P+1I	NULL
than	NULL
in	NULL
extracts	NULL
from	NULL
ionomycin-treated	NULL
cells	NULL
.	NULL

This	NULL
was	NULL
also	NULL
true	NULL
for	NULL
NFATp	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
PMA-induced	NULL
phosphorylation	NULL
is	NULL
not	NULL
required	NULL
for	NULL
nuclear	NULL
translocation	NULL
of	NULL
NFATp	NULL
,	NULL
which	NULL
occurs	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
ionomycin	NULL
alone	NULL
,	NULL
but	NULL
may	NULL
possibly	NULL
contribute	NULL
to	NULL
DNA	NULL
binding	NULL
,	NULL
to	NULL
transcriptional	NULL
activity	NULL
,	NULL
or	NULL
to	NULL
interaction	NULL
with	NULL
other	NULL
transcription	NULL
factors	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
William	NULL
Bere	NULL
for	NULL
T-cell	NULL
purification	NULL
,	NULL
to	NULL
Suzanne	NULL
Specht	NULL
for	NULL
peptide	NULL
coupling	NULL
and	NULL
antiserum	NULL
production	NULL
,	NULL
to	NULL
Gerald	NULL
Crabtree	NULL
for	NULL
the	NULL
NFAT	NULL
expression	NULL
vector	NULL
and	NULL
monoclonal	NULL
antibody	NULL
7A6	NULL
,	NULL
to	NULL
Timothy	NULL
Hoey	NULL
for	NULL
human	NULL
NFATp	NULL
,	NULL
NFAT3	NULL
,	NULL
and	NULL
NFAT4a	NULL
,	NULL
and	NULL
to	NULL
Carol	NULL
Shawver	NULL
for	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
research	NULL
was	NULL
sponsored	NULL
in	NULL
part	NULL
by	NULL
the	NULL
National	NULL
Cancer	NULL
Insti-tute	NULL
,	NULL
DHHS	NULL
,	NULL
under	NULL
contract	NULL
with	NULL
ABL	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Aramburu	NULL
,	NULL
J.	NULL
,	NULL
L.	NULL
Azzoni	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
B.	NULL
Perussia	NULL
.	NULL

1995	NULL
.	NULL

Activation	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
nuclear	NULL
factors	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
NFATp	NULL
and	NULL
NFATc	NULL
,	NULL
in	NULL
human	NULL
natural	NULL
killer	NULL
cells	NULL
:	NULL
regulation	NULL
upon	NULL
CD16	NULL
ligand	NULL
binding	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:801-810	NULL
.	NULL

2	NULL
.	NULL

Choi	NULL
,	NULL
M.	NULL
S.	NULL
K.	NULL
,	NULL
R.	NULL
D.	NULL
Brines	NULL
,	NULL
M.	NULL
J.	NULL
Holman	NULL
,	NULL
and	NULL
G.	NULL
G.	NULL
B.	NULL
Klaus	NULL
.	NULL

1994	NULL
.	NULL

Induction	NULL
of	NULL
NF-AT	NULL
in	NULL
normal	NULL
B	NULL
lymphocytes	NULL
by	NULL
anti-immunoglobulin	NULL
or	NULL
CD40	NULL
ligand	NULL
in	NULL
conjunction	NULL
with	NULL
IL-4	NULL
.	NULL

Immunity	NULL
1:179-187	NULL
.	NULL

3	NULL
.	NULL

Chuypilo	NULL
,	NULL
S.	NULL
,	NULL
C.	NULL
Schomberg	NULL
,	NULL
R.	NULL
Gerwig	NULL
,	NULL
A.	NULL
Heinfling	NULL
,	NULL
R.	NULL
Reeves	NULL
,	NULL
F.	NULL
Grummt	NULL
,	NULL
and	NULL
E.	NULL
Serfling	NULL
.	NULL

1993	NULL
.	NULL

Multiple	NULL
closely-linked	NULL
NFAT/octamer	NULL
and	NULL
HMGI	NULL
(	NULL
Y	NULL
)	NULL
binding	NULL
sites	NULL
are	NULL
part	NULL
of	NULL
the	NULL
interleukin-4	NULL
promoter	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

21:5694-5704	NULL
.	NULL

4	NULL
.	NULL

Cockerill	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
A.	NULL
G.	NULL
Bert	NULL
,	NULL
F.	NULL
Jenkins	NULL
,	NULL
G.	NULL
R.	NULL
Ryan	NULL
,	NULL
M.	NULL
F.	NULL
Shannon	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Vadas	NULL
.	NULL

1995	NULL
.	NULL

Human	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
enhancer	NULL
function	NULL
is	NULL
associated	NULL
with	NULL
cooperative	NULL
interactions	NULL
between	NULL
AP-1	NULL
and	NULL
NFATp/c	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2071-2079	NULL
.	NULL

5	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Clipstone	NULL
.	NULL

1994	NULL
.	NULL

Signal	NULL
transmission	NULL
between	NULL
the	NULL
plasma	NULL
membrane	NULL
and	NULL
nucleus	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63:1045-1083	NULL
.	NULL

6	NULL
.	NULL

Ghosh	NULL
,	NULL
P.	NULL
,	NULL
A.	NULL
Sica	NULL
,	NULL
M.	NULL
Cippitelli	NULL
,	NULL
J.	NULL
Subleski	NULL
,	NULL
R.	NULL
Lahesmaa	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

Young	NULL
,	NULL
and	NULL
N.	NULL
R.	NULL
Rice	NULL
.	NULL

1996	NULL
.	NULL

Activation	NULL
of	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
in	NULL
a	NULL
cyclosporin	NULL
A-resistant	NULL
pathway	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:7700-7704	NULL
.	NULL

~	NULL
go	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

NFAT	NULL
PROTEINS	NULL
IN	NULL
NORMAL	NULL
HUMAN	NULL
T	NULL
CELLS	NULL
-	NULL
2483	NULL
Goldfeld	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
J.	NULL
L.	NULL
Strominger	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1993	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
novel	NULL
cyclosporin-sensitive	NULL
element	NULL
in	NULL
the	NULL
human	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
gene	NULL
promoter	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:1365-1379	NULL
.	NULL

Ho	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
.	NULL

1994	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFATp	NULL
in	NULL
a	NULL
neuronal	NULL
cell	NULL
line	NULL
and	NULL
in	NULL
the	NULL
murine	NULL
nervous	NULL
system	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:28181-28186	NULL
.	NULL

Ho	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
D.	NULL
J.	NULL
Thomas	NULL
,	NULL
L.	NULL
A.	NULL
Timmerman	NULL
,	NULL
X.	NULL
Li	NULL
,	NULL
U.	NULL
Francke	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1995	NULL
.	NULL

NFATc3	NULL
,	NULL
a	NULL
lymphoid-specific	NULL
NFATc	NULL
family	NULL
member	NULL
that	NULL
is	NULL
calcium-regulated	NULL
and	NULL
exhibits	NULL
distinct	NULL
DNA	NULL
binding	NULL
specificity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:19898-19907	NULL
.	NULL

Hodge	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
A.	NULL
M.	NULL
Ranger	NULL
,	NULL
F.	NULL
C.	NULL
de	NULL
la	NULL
Brousse	NULL
,	NULL
T.	NULL
Hoey	NULL
,	NULL
M.	NULL
J.	NULL
Grusby	NULL
,	NULL
and	NULL
L.	NULL
H.	NULL
Glimcher	NULL
.	NULL

1996	NULL
.	NULL

Hyperproliferation	NULL
and	NULL
dysregulation	NULL
of	NULL
IL-4	NULL
expression	NULL
in	NULL
NF-ATp-deficient	NULL
mice	NULL
.	NULL

Immunity	NULL
4397-405	NULL
.	NULL

Hoey	NULL
,	NULL
T.	NULL
,	NULL
Y.-L.	NULL
Sun	NULL
,	NULL
K.	NULL
Williamson	NULL
,	NULL
and	NULL
X.	NULL
Xu	NULL
.	NULL

1995	NULL
.	NULL

Isolation	NULL
of	NULL
two	NULL
new	NULL
members	NULL
of	NULL
the	NULL
NF-AT	NULL
gene	NULL
family	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
the	NULL
NF-AT	NULL
proteins	NULL
.	NULL

Immunity	NULL
2461-472	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
T.	NULL
M.	NULL
Badalian	NULL
,	NULL
P.	NULL
G.	NULL
Hogan	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

19952	NULL
.	NULL

A	NULL
similar	NULL
DNA-binding	NULL
motif	NULL
in	NULL
NFAT	NULL
family	NULL
proteins	NULL
and	NULL
the	NULL
Rel	NULL
homology	NULL
region	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:4138-4145	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Loh	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1995b	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

7:333-342	NULL
.	NULL

Kozak	NULL
,	NULL
M.	NULL
1987	NULL
.	NULL

An	NULL
analysis	NULL
of	NULL
the	NULL
5'-noncoding	NULL
sequences	NULL
from	NULL
699	NULL
vertebrate	NULL
messenger	NULL
RNAs	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

15:8125-8148	NULL
.	NULL

Liu	NULL
,	NULL
F.-T.	NULL
,	NULL
M.	NULL
Zinnecker	NULL
,	NULL
T.	NULL
Hamaoka	NULL
,	NULL
and	NULL
D.	NULL
H.	NULL
Katz	NULL
.	NULL

1979	NULL
.	NULL

New	NULL
procedures	NULL
for	NULL
preparation	NULL
and	NULL
isolation	NULL
of	NULL
conjugates	NULL
of	NULL
proteins	NULL
and	NULL
a	NULL
synthetic	NULL
copolymer	NULL
of	NULL
p-amino	NULL
acids	NULL
and	NULL
immunochemical	NULL
characterization	NULL
of	NULL
such	NULL
conjugates	NULL
.	NULL

Biochemistry	NULL
.	NULL

18:690-697	NULL
.	NULL

Loh	NULL
,	NULL
C.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Carew	NULL
,	NULL
J.	NULL
Kim	NULL
,	NULL
P.	NULL
G.	NULL
Hogan	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

T-cell	NULL
receptor	NULL
stimulation	NULL
elicits	NULL
an	NULL
early	NULL
phase	NULL
of	NULL
activation	NULL
and	NULL
a	NULL
later	NULL
phase	NULL
of	NULL
deacti-vation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT1	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:3945-3954	NULL
.	NULL

Loh	NULL
,	NULL
C.	NULL
,	NULL
K.	NULL
T.-¥	NULL
.	NULL

Shaw	NULL
,	NULL
J.	NULL
Carew	NULL
,	NULL
J.	NULL
P.	NULL
B.	NULL
Viola	NULL
,	NULL
C.	NULL
Luo	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Perrino	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

Calcineurin	NULL
binds	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT1	NULL
and	NULL
revers-ibly	NULL
regulates	NULL
its	NULL
activity	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:10884-10891	NULL
.	NULL

Luo	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Carew	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
T.	NULL
M.	NULL
Badalian	NULL
,	NULL
W.	NULL
S.	NULL
Lane	NULL
,	NULL
P.	NULL
G.	NULL
Hogan	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

Recombinant	NULL
NFAT1	NULL
(	NULL
NFATp	NULL
)	NULL
is	NULL
regulated	NULL
by	NULL
calcineurin	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
mediates	NULL
transcription	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:3955-3966	NULL
.	NULL

Luo	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

Mechanisms	NULL
of	NULL
transactivation	NULL
by	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells-1	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:141-147	NULL
.	NULL

Luo	NULL
,	NULL
C.	NULL
,	NULL
K.	NULL
T.-Y	NULL
.	NULL

Shaw	NULL
,	NULL
A.	NULL
Raghavan	NULL
,	NULL
J.	NULL
Aramburu	NULL
,	NULL
F.	NULL
Garcia-Cozar	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Perrino	NULL
,	NULL
P.	NULL
G.	NULL
Hogan	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

Interaction	NULL
of	NULL
calcineurin	NULL
with	NULL
a	NULL
domain	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT1	NULL
that	NULL
controls	NULL
nuclear	NULL
import	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:8907-8912	NULL
.	NULL

Masuda	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Y.	NULL
Naito	NULL
,	NULL
H.	NULL
Tokumitsu	NULL
,	NULL
D.	NULL
Campbell	NULL
,	NULL
F.	NULL
Saito	NULL
,	NULL
C.	NULL
Hannum	NULL
,	NULL
K.-I	NULL
.	NULL

Arai	NULL
,	NULL
and	NULL
N.	NULL
Arai	NULL
.	NULL

1995	NULL
.	NULL

NFATsz	NULL
,	NULL
a	NULL
novel	NULL
member	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
family	NULL
that	NULL
is	NULL
expressed	NULL
predominantly	NULL
in	NULL
the	NULL
thymus	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2697-2706	NULL
.	NULL

Masuda	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
H.	NULL
Tokumitsu	NULL
,	NULL
A.	NULL
Tsuboi	NULL
,	NULL
J.	NULL
Shlomai	NULL
,	NULL
P.	NULL
Hung	NULL
,	NULL
K.-L.	NULL
Arai	NULL
,	NULL
and	NULL
N.	NULL
Arai	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
promoter	NULL
cis-acting	NULL
element	NULL
CLEO	NULL
mediates	NULL
induction	NULL
signals	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
is	NULL
recognized	NULL
by	NULL
factors	NULL
related	NULL
to	NULL
AP1	NULL
and	NULL
NFAT	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:7399-7407	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
A.	NULL
E.	NULL
Goldfeld	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
role	NULL
of	NULL
NFATp	NULL
in	NULL
cyclosporin	NULL
A-sensitive	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
gene	NULL
transcription	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:30445-30450	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
C.	NULL
Luo	NULL
,	NULL
T.	NULL
K.	NULL
Kerppola	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
T.	NULL
M.	NULL
Badalian	NULL
,	NULL
A.	NULL
M.	NULL
Ho	NULL
,	NULL
E.	NULL
Burgeon	NULL
,	NULL
W.	NULL
S.	NULL
Lane	NULL
,	NULL
J.	NULL
N.	NULL
Lambert	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
G.	NULL
L.	NULL
Verdine	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
.	NULL

1993	NULL
.	NULL

Isolation	NULL
of	NULL
the	NULL
cyclosporin-sensitive	NULL
T	NULL
cell	NULL
transcription	NULL
factor	NULL
NFATp	NULL
.	NULL

Science	NULL
262:750-754.	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Perrino	NULL
,	NULL
T.	NULL
R.	NULL
Soderling	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1993	NULL
.	NULL

NF-ATp	NULL
,	NULL
a	NULL
T	NULL
lymphocyte	NULL
DNA-binding	NULL
protein	NULL
that	NULL
is	NULL
a	NULL
target	NULL
for	NULL
calcineurin	NULL
and	NULL
immunosuppressive	NULL
drugs	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:3747-3752	NULL
.	NULL

Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
S.	NULL
N.	NULL
Ho	NULL
,	NULL
L.	NULL
Chen	NULL
,	NULL
D.	NULL
J.	NULL
Thomas	NULL
,	NULL
L.	NULL
A.	NULL
Timmerman	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1994	NULL
.	NULL

NF-AT	NULL
components	NULL
define	NULL
a	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
targeted	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
369:497-502	NULL
.	NULL

Park	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
Takeuchi	NULL
,	NULL
and	NULL
S.	NULL
Sharma	NULL
.	NULL

1996	NULL
.	NULL

Characterization	NULL
of	NULL
a	NULL
new	NULL
isoform	NULL
of	NULL
the	NULL
NFAT	NULL
(	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
)	NULL
gene	NULL
family	NULL
member	NULL
NFATe	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:20914-20921	NULL
.	NULL

Park	NULL
,	NULL
J.	NULL
,	NULL
N.	NULL
R.	NULL
Yaseen	NULL
,	NULL
P.	NULL
G.	NULL
Hogan	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
S.	NULL
Sharma	NULL
.	NULL

1995	NULL
.	NULL

Phosphorylation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NFATp	NULL
inhibits	NULL
its	NULL
DNA	NULL
binding	NULL
activity	NULL
in	NULL
cyclosporin	NULL
A-treated	NULL
human	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
:	NULL
20653-20659	NULL
.	NULL

Priesch	NULL
]	NULL
,	NULL
E.	NULL
E.	NULL
,	NULL
V.	NULL
Gouilleux-Gruart	NULL
,	NULL
C.	NULL
Walker	NULL
,	NULL
N.	NULL
E.	NULL
Harrer	NULL
,	NULL
and	NULL
T.	NULL
Baum-ruker	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cell-like	NULL
transcription	NULL
factor	NULL
in	NULL
mast	NULL
cells	NULL
is	NULL
involved	NULL
in	NULL
IL-5	NULL
gene	NULL
regulation	NULL
after	NULL
IgE	NULL
plus	NULL
antigen	NULL
stimu-lation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:6112-6119	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

1994	NULL
.	NULL

NF-ATp	NULL
:	NULL
a	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
the	NULL
co-ordinate	NULL
induction	NULL
of	NULL
several	NULL
cytokine	NULL
genes	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
15:274-281	NULL
.	NULL

Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
and	NULL
M.	NULL
K.	NULL
Ernst	NULL
.	NULL

1993	NULL
.	NULL

In	NULL
vivo	NULL
control	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
by	NULL
IxBa	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:4685-4695	NULL
.	NULL

Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
M.	NULL
L.	NULL
MacKichan	NULL
,	NULL
and	NULL
A.	NULL
Israél	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
precursor	NULL
of	NULL
NF-kB	NULL
2484	NULL
33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

LYAKH	NULL
ET	NULL
AL	NULL
.	NULL

p50	NULL
has	NULL
IxB-like	NULL
functions	NULL
.	NULL

Cell	NULL
71:243-252	NULL
.	NULL

Rooney	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
T.	NULL
Hoey	NULL
,	NULL
and	NULL
L.	NULL
H.	NULL
Glimcher	NULL
.	NULL

1995	NULL
.	NULL

Coordinate	NULL
and	NULL
cooperative	NULL
roles	NULL
for	NULL
NFAT	NULL
and	NULL
AP-1	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
murine	NULL
IL-4	NULL
gene	NULL
.	NULL

Immunity	NULL
2473-483	NULL
.	NULL

Ruff	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
and	NULL
K.	NULL
L.	NULL
Leach	NULL
.	NULL

1995	NULL
.	NULL

Direct	NULL
demonstration	NULL
of	NULL
NFATp	NULL
dephosphorylation	NULL
and	NULL
nuclear	NULL
localization	NULL
in	NULL
activated	NULL
HT-2	NULL
cells	NULL
using	NULL
a	NULL
specific	NULL
NFATp	NULL
polyclonal	NULL
antibody	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:22602-22607	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
A.	NULL
Avots	NULL
,	NULL
and	NULL
M.	NULL
Neumann	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
architecture	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
:	NULL
a	NULL
reflection	NULL
of	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1263:181-200	NULL
.	NULL

Shaw	NULL
,	NULL
K	NULL
.	NULL

T.-Y	NULL
.	NULL

,	NULL
A.	NULL
M.	NULL
Ho	NULL
,	NULL
A.	NULL
Raghavan	NULL
,	NULL
J.	NULL
Kim	NULL
,	NULL
J.	NULL
Jain	NULL
,	NULL
J	NULL
.	NULL

Park	NULL
,	NULL
S.	NULL
Sharma	NULL
,	NULL
A.	NULL
Rao	NULL
,	NULL
and	NULL
P.	NULL
G.	NULL
Hogan	NULL
.	NULL

1995	NULL
.	NULL

Immunosuppressive	NULL
drugs	NULL
prevent	NULL
a	NULL
rapid	NULL
dephosphorylation	NULL
of	NULL
transcription	NULL
factor	NULL
NFAT1	NULL
in	NULL
stimulated	NULL
immune	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:11205-11209	NULL
.	NULL

Shibasaki	NULL
,	NULL
F.	NULL
,	NULL
E.	NULL
R.	NULL
Price	NULL
,	NULL
D.	NULL
Milan	NULL
,	NULL
and	NULL
F.	NULL
McKeon	NULL
.	NULL

1996	NULL
.	NULL

Role	NULL
of	NULL
kinases	NULL
and	NULL
the	NULL
phosphatase	NULL
calcineurin	NULL
in	NULL
the	NULL
nuclear	NULL
shuttling	NULL
of	NULL
transcription	NULL
factor	NULL
NF-AT4	NULL
.	NULL

Nature	NULL
382:370-373	NULL
.	NULL

Szabo	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
J.	NULL
S.	NULL
Gold	NULL
,	NULL
T.	NULL
L.	NULL
Murphy	NULL
,	NULL
and	NULL
K.	NULL
M.	NULL
Murphy	NULL
.	NULL

1993	NULL
.	NULL

Identification	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
elements	NULL
controlling	NULL
interleukin-4	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
:	NULL
roles	NULL
for	NULL
NF-Y	NULL
and	NULL
NF-ATc	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13:4793-4805	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Ledbetter	NULL
,	NULL
S.	NULL
L.	NULL
Kunkel	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

Young	NULL
,	NULL
S.	NULL
G.	NULL
Emerson	NULL
,	NULL
J.	NULL
M.	NULL
Leiden	NULL
,	NULL
and	NULL
C.	NULL
H.	NULL
June	NULL
.	NULL

1989	NULL
.	NULL

CD28	NULL
activation	NULL
pathway	NULL
40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

regulates	NULL
the	NULL
production	NULL
of	NULL
multiple	NULL
T-cell-derived	NULL
lymphokines/cytokines	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:1333-1337	NULL
.	NULL

Venkataraman	NULL
,	NULL
L.	NULL
,	NULL
D.	NULL
A.	NULL
Francis	NULL
,	NULL
Z.	NULL
Wang	NULL
,	NULL
J.	NULL
Liu	NULL
,	NULL
T.	NULL
L.	NULL
Rothstein	NULL
,	NULL
and	NULL
R.	NULL
Sen.	NULL
1994	NULL
.	NULL

Cyclosporin	NULL
A-sensitive	NULL
induction	NULL
of	NULL
NF-AT	NULL
in	NULL
murine	NULL
B	NULL
cells	NULL
.	NULL

Immunity	NULL
1:189-196	NULL
.	NULL

Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
C.	NULL
Guidos	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1990	NULL
.	NULL

Cell	NULL
type	NULL
specificity	NULL
and	NULL
activation	NULL
requirements	NULL
for	NULL
NFAT-1	NULL
(	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T-cells	NULL
)	NULL
transcriptional	NULL
activity	NULL
determined	NULL
by	NULL
a	NULL
new	NULL
method	NULL
using	NULL
transgenic	NULL
mice	NULL
to	NULL
assay	NULL
transcriptional	NULL
activity	NULL
of	NULL
an	NULL
individual	NULL
nuclear	NULL
factor	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:15788-15795	NULL
.	NULL

Wang	NULL
,	NULL
D.	NULL
Z.	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
cyclosporin-sensitive	NULL
transcription	NULL
factor	NULL
NFATp	NULL
is	NULL
expressed	NULL
in	NULL
several	NULL
classes	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Ann	NULL
.	NULL

N.	NULL
Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

766:182-195	NULL
.	NULL

Wesselborg	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
A.	NULL
Fruman	NULL
,	NULL
J.	NULL
K.	NULL
Sagoo	NULL
,	NULL
B.	NULL
E.	NULL
Bierer	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Burakoff	NULL
.	NULL

1996	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
physical	NULL
interaction	NULL
between	NULL
calcineurin	NULL
and	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFATp	NULL
)	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:1274-1277	NULL
.	NULL

Xanthoudakis	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
P.	NULL
B.	NULL
Viola	NULL
,	NULL
K.	NULL
T.	NULL
Y.	NULL
Shaw	NULL
,	NULL
C.	NULL
Luo	NULL
,	NULL
J.	NULL
D.	NULL
Wallace	NULL
,	NULL
P.	NULL
T.	NULL
Bozza	NULL
,	NULL
T.	NULL
Curran	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1996	NULL
.	NULL

An	NULL
enhanced	NULL
immune	NULL
response	NULL
in	NULL
mice	NULL
lacking	NULL
the	NULL
transcription	NULL
factor	NULL
NFAT1	NULL
.	NULL

Science	NULL
272:892-895	NULL
.	NULL

Yaseen	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
A.	NULL
L.	NULL
Maizel	NULL
,	NULL
F.	NULL
Wang	NULL
,	NULL
and	NULL
S.	NULL
Sharma	NULL
.	NULL

1993	NULL
.	NULL

Comparative	NULL
analysis	NULL
of	NULL
NFAT	NULL
(	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
)	NULL
complex	NULL
in	NULL
human	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:14285-14293	NULL
.	NULL

